UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

(Mark One)

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended ~~December~~March 31, ~~2024~~2025

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from __________ to __________

Commission File Number: 000-51390

INNOVATIVE MEDTECH, INC.

(Exact name of registrant as specified in its charter)

Delaware		33-1130446
(State or other jurisdiction of incorporation or organization)		(I.R.S. Employer Identification No.)

2310 York St., Suite 200 Blue Island, IL		60406
(Address of principal executive offices)		(Zip Code)

(708) 925-9424

(Registrant’s telephone number, including area code)

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading

Symbol(s)

Name of each exchange

on which registered

Not applicable.

Note applicable.

Not applicable.

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act:

Large accelerated filer	☐	Accelerated filer	☐
Non-accelerated filer	☒	Smaller reporting company	☒
		Emerging growth company	☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). Yes ☐ No ☒

As of ~~February~~May 1820, 2025, there were 5253,~~518~~706,~~963~~463 shares of Common Stock, $0.000001 par value per share, issued and outstanding.

Innovative MedTech, Inc.

Form 10-Q

TABLE OF CONTENTS

PART I - FINANCIAL INFORMATION		4
Item 1.	Financial Statements (unaudited)	4
Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	31
Item 3.	Quantitative and Qualitative Disclosures About Market Risk	3635
Item 4.	Controls and Procedures	3635
PART II - OTHER INFORMATION		3837
Item 1.	Legal Proceedings	3837
Item 1A.	Risk Factors	38
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	38
Item 3.	Defaults Upon Senior Securities	38
Item 4.	Mine Safety Disclosures	38
Item 5.	Other Information	38
Item 6.	Exhibits	39
Exhibit Index		39
Signatures		40

Table of Contents

NOTE REGARDING FORWARD-LOOKING STATEMENTS

Unless stated otherwise or the context otherwise requires, the words “we,” “us,” “our,” the “Company,” “Innovative MedTech” or “Innovative” in this Quarterly Report on Form 10-Q collectively refers to Innovative MedTech, Inc., a Delaware corporation (the “Company”), and its subsidiaries. The information in this Quarterly Report on Form 10-Q/A contains “forward-looking statements” relating to the Company, within the meaning of Section 27 as of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). In some cases, you can identify forward-looking statements by terminology such as “may”, “should”, “expects”, “plans”, “anticipates”, “believes”, “estimates”, “predicts”, “potential” or “continue” or the negative of these terms or other comparable terminology. These statements are only predictions and involve known and unknown risks, uncertainties and other factors that may cause our or our industry’s actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements.

While these forward-looking statements, and any assumptions upon which they are based, are made in good faith and reflect our current judgment regarding the direction of our business, actual results will almost always vary, sometimes materially, from any estimates, predictions, projections, assumptions or other future performance suggested herein. Except as required by applicable law, including the securities laws of the United States, we do not intend to update any of the forward-looking statements to conform these statements to actual results.

This report contains information that may be deemed forward-looking, that is based largely on the Company’s current expectations, and is subject to certain risks, trends and uncertainties that could cause actual results to differ materially from those anticipated.

Among such risks, trends and other uncertainties, which in some instances are beyond its control, may be the Company’s ability to generate cash flows and maintain liquidity sufficient to service its debt, and comply with or obtain amendments or waivers of the financial covenants contained in its credit facilities, if necessary. Other risks and uncertainties include the impact of continuing adverse economic conditions, potential changes in the adult day care industry, energy costs, interest rates and the availability of credit, labor costs, legislative and regulatory rulings and other results of operations or financial conditions, increased capital and other costs, competition and other risks detailed from time to time in the Company’s publicly filed documents.

The words “may”, “will”, “would”, “could”, “believes”, “expects”, “anticipates”, “intends”, “plans”, “projects”, “considers” and similar expressions generally identify forward-looking statements. Readers are cautioned not to place undue reliance on such forward-looking statements, which are made as of the date of this report. The Company does not undertake to publicly update or revise its forward-looking statements.

Table of Contents

PART I – FINANCIAL INFORMATION

Item 1. FINANCIAL STATEMENTS

INNOVATIVE MEDTECH, INC. (FORMERLY FRESH HARVEST PRODUCTS, INC.) AND SUBSIDIARIES
CONSOLIDATED BALANCE SHEETSUNAUDITED
CONSOLIDATED BALANCE SHEETS
	December 31,2024			June 30,2024
	March 31, 2025			June 30, 2024
	(unaudited)
Assets
Current assets
Cash and cash equivalents	$	98351		$	873
Notes receivable, related party		9,294			9,294
Assets of discontinued operations, current		~~256~~240,~~500~~741			273,612
Total current assets		~~265~~250,~~892~~386			283,779
Deposit on business acquisition		540,800			-
Assets of discontinued operations, non-current		~~325~~272,~~494~~030			368,102
Total Assets	$	1,~~132~~063,~~186~~216		$	651,881
Liabilities & Stockholders' Deficit
Liabilities & Stockholders’ Deficit
Current liabilities
Accounts payable and accrued expenses	$	~~247~~285,~~600~~101		$	498,217
Accrued interest		~~668~~684,~~198~~068			633,868
Accrued interest, related parties		~~181~~192,~~370~~847			152,079
Notes payable, related parties, current		674,271			674,271
Notes payable, current		~~388~~382,~~864~~526			263,931
Convertible notes payable, current		266,900			266,900
Derivative liability		~~201~~202,~~292~~550			193,557
Liabilities of discontinued operations, current		1,~~362~~327,~~873~~456			1,418,534
Total current liabilities		34,~~991~~015,~~368~~719			4,101,357
Royalty liability		1,500,000			1,500,000
Liabilities of discontinued operations, non-current		~~485~~439,~~286~~715			533,486
Total Liabilities		5,~~976~~955,~~654~~434			6,134,843
Commitments and contingencies (Note 13)
Commitments and contingencies (Note 14)
Stockholders' Deficit
Stockholders’ Deficit
Series A Preferred stock, $0.000001 par value; 500,000,000 authorized: 367,500 shares issued and outstanding		-			-
Common stock, $0.000001 par value; 130,000,000 shares authorized; 52,518,963 and 23,882,297 shares issued and outstanding as of December 31, 2024 and June 30, 2024, respectively		53			24
Common stock, $0.000001 par value; 130,000,000 shares authorized; 53,338,963 and 23,882,297 shares issued and outstanding as of March 31, 2025 and June 30, 2024, respectively		54			24
Additional paid in capital		41,~~724~~765,~~553~~552			39,078,224
Accumulated deficit		(46,~~569~~657,~~074~~824	)		(44,561,210	)
Total Stockholders' Deficit		(4,844,468	)		(5,482,962	)
Total Stockholders’ Deficit		(4,892,218	)		(5,482,962	)
Total Liabilities and Stockholders' Deficit	$	1,132,186		$	651,881
Total Liabilities and Stockholders’ Deficit	$	1,063,216		$	651,881

See accompanying notes to unaudited consolidated financial statements.

Table of Contents

INNOVATIVE MEDTECH, INC. (FORMERLY FRESH HARVEST PRODUCTS, INC.) AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF OPERATIONSUNAUDITED
	For the three months ended						For the ~~six~~nine months ended
	December 31,						December 31,
	March 31,						March 31,
	2024			2023			2024			2023
	2025			2024			2025			2024
Revenue:
Participant fees	$	-		$	-		$	-		$	-
Franchise fees		-			-			-			-
Operating expenses:
General and administrative		~~17,419~~(841	)		5,~~462~~152			2423,~~064~~223			1419,~~513~~665
Stock-based compensation		~~75,567~~-			-			104,308			-
Consulting fees		~~937~~37,500			41841,~~507~~042			1,~~746~~783,~~250~~750			93934,~~074~~116
Legal and professional fees		4320,~~690~~000			4619,~~865~~000			97117,050			83102,644
Total operating expenses		156,~~074,176~~659			93865,~~834~~194			12,~~971~~028,~~672~~331			~~191~~1,~~231~~056,425
Loss from operations		(156,~~074,176~~659	)		(93865,~~834~~194	)		(12,~~971~~028,~~672~~331	)		(~~191~~1,~~231~~056,425	)
Other income (expense):
Other (expense) income:
Interest expense, related parties		-(11,175	)		~~(16,100~~-	)		(1829,~~639~~814	)		(33,040	)
Interest expense		(2942,~~940~~497	)		(1030,~~352~~690	)		(4688,~~224~~721	)		(1849,~~850~~540	)
Change in fair value of derivatives		(1,~~292~~258	)		530,~~165~~779			(78,~~735~~993	)		~~(19~~11,~~568~~211	)
Amortization of debt discount		(35,~~632~~921	)		~~(14,796~~-	)		(612,~~079~~000	)		(22,849	)
Total other income (expense)		(34,864	)		(36,083	)		(78,677	)		(94,307	)
Total other (expense) income		(60,851	)		89			(139,528	)		(94,218	)
Net loss from continuing operations	$	(1117,~~109,040~~510	)	$	(~~129~~865,~~917~~105	)	$	(2,~~050~~167,~~349~~859	)	$	(~~285~~1,~~538~~150,643	)
Discontinued operations
Gain (loss) from operations of discontinued operations		~~(15~~28,~~293~~760	)		(5844,~~228~~767	)		4271,~~485~~245			(67112,~~670~~437	)
Total discontinued operations		~~(15~~28,~~293~~760	)		(5844,~~228~~767	)		4271,~~485~~245			(67112,~~670~~437	)
Loss before tax benefit (expense)		(188,~~124,333~~750	)		(~~188~~909,~~145~~872	)		(2,~~007~~096,~~864~~614	)		(~~353~~1,~~208~~263,080	)
Income tax benefit (expense)		-			-			-			-
Net loss applicable to common stockholders		(188,~~124,333~~750	)		(~~188~~909,~~145~~872	)		(2,~~007~~096,~~864~~614	)		(~~353~~1,~~208~~263,080	)
Basic and diluted earnings per share on net loss	$	(0.0400	)	$	(0.0104	)	$	(0.0706	)	$	(0.0206	)
Weighted average shares outstanding - basic and diluted		3052,~~892~~684,~~589~~806			21,157,327			2736,~~809~~009,~~455~~513			21,157,327

See accompanying notes to unaudited consolidated financial statements

Table of Contents

INNOVATIVE MEDTECH, INC.(FORMERLY FRESH HARVEST PRODUCTS, INC.)AND SUBSIDIARIES STATEMENTS OF CHANGES IN STOCKHOLDERS' DEFICIT For the three and nine months ended March 31, 2025 and 2024Unaudited

(FORMERLY FRESH HARVEST PRODUCTS, INC.)

	Series A Preferred Stock				Common Stock				Additional Paid-in		Accumulated			Stockholders'
	Shares		Amount		Shares		Amount		Capital		Deficit			Deficit
Balance, June 30, 2024		367,500	$	-		23,882,297	$	24	$	39,078,224	$	(44,561,210	)	$	(5,482,962	)

Stock issued for services		-		-		2,036,666		2		771,248		-			771,250

Stock issued for deposit in joint venture		-		-		2,000,000		2		540,798		-			540,800

Stock-based compensation		-		-		-		-		28,741		-			28,741

Net loss		-		-		-		-		-		(883,531	)		(883,531	)

Balance, September 30, 2024		367,500		-		27,918,963		28		40,419,011		(45,444,741	)		(5,025,702	)

Stock issued for services		-		-		18,100,000		18		904,982		-			905,000

Stock issued for satisfaction of accounts payable		-		-		6,500,000		7		324,993		-			325,000

Stock-based compensation		-		-		-		-		75,567		-			75,567

Net loss		-		-		-		-		-		(1,124,333	)		(1,124,333	)

Balance, December 31, 2024		367,500	$	-		52,518,963	$	53	$	41,724,553	$	(46,569,074	)	$	(4,844,468	)

Sale of common stock		-		-		820,000		1		40,999		-			41,000

Net loss		-		-		-		-		-		(88,750	)		(88,750	)

Balance, March 31, 2025		367,500	$	-		53,338,963	$	54	$	41,765,552	$	(46,657,824	)	$	(4,892,218	)

AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' DEFICIT

FOR THE THREE AND SIX MONTHS ENDED DECEMBER 31, 2024

UNAUDITED

	Series A Preferred Stock				Common Stock				AdditionalPaid-In		Accumulated			Stockholders’
	Shares		Amount		Shares		Amount		Capital		Deficit			Deficit
Balance, June 30, 2024		367,500	$	—		23,882,297	$	24	$	39,078,224	$	(44,561,210	)	$	(5,482,962	)
Stock issued for services		—		—		2,036,666		2		771,248		—			771,250
Stock issued for deposit in joint venture		—		—		2,000,000		2		540,798		—			540,800
Stock-based compensation		—		—		—		—		28,741		—			28,741
Net loss		—		—		—		—		—		(883,531	)		(883,531	)
Balance, September 30, 2024		367,500		—		27,918,963		28		40,419,011		(45,444,741	)		(5,025,702	)
Stock issued for services		—		—		18,100,000		18		904,982		—			905,000
Stock issued for satisfaction of accounts payable		—		—		6,500,000		7		324,993		—			325,000
Stock-based compensation		—		—		—		—		75,567		—			75,567
Net loss		—		—		—		—		—		(1,124,333	)		(1,124,333	)
Balance, December 31, 2024		367,500	$	—		52,518,963	$	53	$	41,724,553	$	(46,569,074	)	$	(4,844,468	)

See accompanying notes to unaudited consolidated financial statements

Table of Contents

INNOVATIVE MEDTECH, INC. (FORMERLY FRESH HARVEST PRODUCTS, INC.) AND SUBSIDIARIES STATEMENTS OF CHANGES IN STOCKHOLDERS’ DEFICIT For the three and nine months ended March 31, 2024 Unaudited

(FORMERLY FRESH HARVEST PRODUCTS, INC.)

	Series A Preferred Stock				Common Stock				Paid -in		Accumulated			Stockholders'
	Shares		Amount		Shares		Amount		Capital		Deficit			Deficit
Balance, June 30, 2023		367,500	$	-		21,157,327	$	21	$	35,313,906	$	(36,622,313	)	$	(1,308,386	)

Warrants issued with notes payable		-		-		-		-		22,849		-			22,849

Net loss		-		-		-		-		-		(165,063	)		(165,063	)

Balance, September 30, 2023		367,500		-		21,157,327		21		35,336,755		(36,787,376	)		(1,450,600	)

Net loss		-		-		-		-		-		(188,145	)		(188,145	)

Balance, December 31, 2023		367,500		-		21,157,327		21		35,336,755		(36,975,521	)		(1,638,745	)

Stock issued for services		-		-		1,590,728		2		1,171,918		-			1,171,920

Net loss		-		-		-		-		-		(909,872	)		(909,872	)

Balance, March 31, 2024		367,500	$	-		22,748,055	$	23	$	36,508,673	$	(37,885,393	)	$	(1,376,697	)

AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' DEFICIT

FOR THE THREE AND SIX MONTHS ENDED DECEMBER 31, 2023

UNAUDITED

	Series A Preferred Stock				Common Stock				AdditionalPaid-In		Accumulated			Stockholders’
	Shares		Amount		Shares		Amount		Capital		Deficit			Deficit
Balance, June 30, 2023		417,500	$	—		21,157,327	$	21	$	35,313,906	$	(36,622,313	)	$	(1,308,386	)
Warrants issued with notes payable		—		—		—		—		22,849		—			22,849
Net loss		—		—		—		—		—		(165,063	)		(165,063	)
Balance, September 30, 2023		417,500		—		21,157,327		21		35,336,755		(36,787,376	)		(1,450,600	)
Net loss		—		—		—		—		—		(188,145	)		(188,145	)
Balance, December 31, 2023		417,500	$	—		21,157,327	$	21	$	35,336,755	$	(36,975,521	)	$	(1,638,745	)

See accompanying notes to unaudited consolidated financial statements

Table of Contents

INNOVATIVE MEDTECH, INC.(FORMERLY FRESH HARVEST PRODUCTS, INC.) AND SUBSIDIARIES
INNOVATIVE MEDTECH, INC. (FORMERLY FRESH HARVEST PRODUCTS, INC.) AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF CASH FLOWSUNAUDITED
CONSOLIDATED STATEMENTS OF CASH FLOWS
	For the six months ended
	For the nine months ended
	December 31,
	March 31,
	2024			2023
	2025 (unaudited)			2024(unaudited)
Cash Flows from Operating Activities
Net Loss	$	(2,~~007~~096,~~864~~614	)	$	(~~353~~1,~~208~~263,080	)
Adjustments to reconcile net loss to net
Adjustments to reconcile net loss to net cash used by operating activities:
cash used by operating activities:
Stock-based compensation		104,308			-
Stock issued for services		1,676,250			-1,194,767
Amortization of royalty fee liability discount		-			151
Change in fair value of derivatives		78,~~735~~993			19(11,~~568~~210	)
Amortization of debt discount		612,~~079~~000			~~22,849~~-
Changes in operating assets & liabilities
Accounts payable and accrued liabilities		74,384			40,693
Prepaid expenses		-			(353,378	)
Accrued interest, related party		29,291			25,024
Accounts payable and accrued liabilities		111,884			113,176
Accrued interest		34,330			26,715
Accrued interest, related party		40,768			41,127
Net change in operating activities from continuing operations		(75,487	)		(218,208	)
Accrued interest		49,128			43,501
Net change in operating activities from continuing operations		(93,283	)		(234,946	)
Cash Flows from Investing Activities
Net change in investing activities from continuing operations		-			-
Cash Flows from Financing Activities
Proceeds from notes payable		137,000			150,000
Sale of common stock		41,000			-
Payments on notes payable		(18,146	)		-
Proceeds from notes payable		135,000			151,350
Net change in financing activities from continuing operations		118,854			150,000
Proceeds from notes payable, related parties		-			22,000
Net change in cash and cash equivalents from continuing operations		43,367			(68,208	)
Payments on notes payable		(27,333	)		-
Net change in financing activities from continuing operations		148,667			173,350
Net change in cash and cash equivalents from continuing operations		55,384			(61,596	)
CASH FLOWS FROM DISCONTINUED OPERATIONS
Net change in operating activities from discontinued operations		~~(40~~128,~~759~~943	)		70143,~~924~~821
Net change in investing activities from discontinued operations		-			-
Net change in financing activities from discontinued operations		(3184,~~383~~849	)		(382,~~258~~732	)
Net change in cash and cash equivalents from discontinued operations		(4455,~~142~~906	)		6761,~~666~~089
Net change in cash and cash equivalents		(~~775~~522	)		(~~542~~507	)
Cash and cash equivalents at beginning of period		873			1,120
Cash and equivalents at end of period	$	98351		$	~~578~~613
Supplemental Cash Flow Information
Cash paid for interest	$	-1,161		$	-
Cash paid for income taxes	$	-		$	-
Non-cash investing and financing activities:
Common stock issued for deposit on business acquisition	$	540,800		$	-
Common stock issued for satisfaction of accounts payable	$	325,000		$	-

See accompanying notes to unaudited consolidated financial statements

Table of Contents

INNOVATIVE MEDTECH, INC.

AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

FOR THE PERIOD ENDING ~~DECEMBER~~MARCH 31, ~~2024~~2025

(UNAUDITED)

NOTE 1. GENERAL ORGANIZATION AND BUSINESS

Innovative MedTech, Inc. (the “Company”), a Delaware corporation, is a provider of health and wellness services, and has two divisions: technology and devices and Adult Day Services. The Company’s technology and devices division has signed a distribution agreement with 2 products: a high detection vein visualization device and an Oral Thrush product, and the Company’s wholly owned subsidiary SarahCare, an adult day care franchisor with 25 centers (1 corporate and 24 franchise locations) located in 13 states. SarahCare offers seniors daytime care and activities focusing on meeting their physical and medical needs on a daily basis, and ranging from nursing care to salon services and providing meals, to offering engaging and enriching activities to allow them to continue to lead active and engaged lives.

On or about April 1625, ~~2024~~2025, Innovative MedTech, Inc. (“Innovative” or the “Company”) entered into aan ~~distribution~~Asset ~~agreement~~Purchase Agreement (the "“Asset Acquisition Agreement"”), ~~with~~pursuant ~~Near~~to ~~Infrared~~which ~~Imaging,~~a ~~Inc.~~newly formed subsidiary of the Company (~~"NII"~~the “New Subsidiary”) ~~for~~would ~~Vein-Eye~~purchase ~~Carry~~(the “Purchase”) assets of Grand Concierge LLC, d/b/a ~~patent-pending~~Ticketbash, ~~vein~~a ~~illumination~~New ~~technology~~York ~~which~~limited ~~employs~~liability ~~advanced~~company ~~optics~~(“Ticketbash”) ~~and~~associated ~~real-time~~with ~~imaging~~retail toand ~~precisely~~wholesale ~~identify~~event ~~veins~~ticket pricing, ~~reducing~~and the ~~need~~development ~~for~~of ~~multiple~~software ~~attempts~~ and ~~enhancing~~artificial ~~procedural~~intelligence ~~accuracy.~~related ~~The~~to ~~Agreement gives~~ the ~~Company~~ticket business (the ~~non-exclusive~~“Assets”), ~~right~~in toconsideration ~~distribute~~of ~~NII's product~~(si) ~~with~~the noissuance ~~limitations~~by on the ~~territory.~~Company ~~NII'~~to Ticketbash’s ~~Vein-Eye~~owners ~~Carry~~of is20,000,000 ashares ~~Class~~of common stock and 1,151,500 ~~510-k~~shares ~~exempt~~of ~~medical~~Series ~~device,~~A Convertible Preferred Stock (which preferred stock is ~~TAA~~convertible into 115,150,000 shares of common stock) (such shares of common stock and ~~FAR~~preferred ~~compliant~~stock collectively the “Shares”), and isadditional ~~designed,~~shares ~~engineered~~as ~~and~~necessary ~~manufactured~~to inensure that the ~~U.S.~~shares ~~The~~issued ~~Vein-Eye~~constitute ~~Carry~~60% isof ~~lightweight~~the ~~and~~total ~~portable~~number of fully diluted shares of the Company, (ii) the future payment of two million dollars ($2,000,000) to Ticketbash based on net revenue and ~~can~~income milestones to be ~~successfully~~determined ~~carried~~by ~~into~~the aparties ~~home~~in the future, upand ~~flights~~(iii) the future payment of ~~stairs,~~percentage ~~carried~~royalties ~~into~~to aTicketbash ~~clinic~~based ~~nursing~~on ~~home,~~aggregate ~~placed~~revenues ingenerated anby ~~ambulance~~the orNew ~~another~~Subsidiary ~~emergency~~as ~~medical~~follows: ~~vehicle. On~~2% ~~December~~of revenue up to $15,000,000, ~~2024~~4% of revenue from $15,000,000-$25,000,000, ~~the~~and ~~Company~~5% ~~was~~of ~~notified~~revenue byin ~~NII~~excess ~~that~~of ~~NII~~$25,000,000. ~~would~~In beconnection ~~exercising~~with the ~~thirty~~Purchase, ~~(30)~~Ticketbash ~~notice~~also ~~for~~received ~~termination~~the right to appoint two members of the ~~Agreement~~Board ~~between~~of Directors of the ~~companies~~Company. On or about April 25, 2025, the Purchase was closed, and Innovative issued the Shares to Ticketbash’s owners.

~~IMTH~~On ~~has~~or ~~recently~~about ~~signed~~April ~~consulting~~16, ~~agreements~~2024, ~~with~~the ~~two~~Company ~~highly~~entered ~~experienced~~into ~~wound~~a ~~care~~distribution ~~specialists~~agreement to(the ~~manage~~“Agreement”) ~~the~~with ~~Company’s~~Near ~~expansion~~Infrared ~~into~~Imaging, ~~the~~Inc. ~~burgeoning~~(“NII”) ~~advanced~~for ~~wound~~Vein-Eye ~~care~~Carry, ~~market. IMTH~~a ~~expects~~patent-pending tovein ~~utilize~~illumination ~~the~~technology ~~biological~~which ~~amnionic~~employs ~~membrane~~advanced ~~allograft~~optics ~~which~~and ~~has~~real-time ~~proven~~imaging to beprecisely aidentify ~~dramatic~~veins, ~~leap~~reducing ~~forward~~the inneed ~~wound~~for ~~care~~multiple ~~with~~attempts aand ~~very~~enhancing ~~high~~procedural ~~success~~accuracy. ~~rate~~The ~~for~~Agreement ~~closing~~gives ~~and~~the ~~healing~~Company ~~infected~~the ~~wounds,~~non-exclusive ~~far~~right ~~beyond~~to ~~anything~~distribute ~~that~~NII’s ~~has~~product(s) ~~previously~~with ~~been~~no ~~achieved~~limitations on the territory. ~~IMTH~~NII’s ~~new~~Vein-Eye ~~consultants~~Carry ~~have~~is ~~contracts~~a ~~with~~Class ~~two~~1, of510-k ~~the~~exempt ~~largest~~medical ~~distributors~~device, ~~for~~is ~~biological~~TAA ~~amnion~~and ~~membrane~~FAR ~~allografts.~~compliant, ~~Their~~and ~~primary~~is ~~objectives~~designed, ~~are~~engineered toand ~~pursue~~manufactured ~~potential~~in ~~wound~~the ~~care~~U.S. ~~acquisitions~~The ~~and~~Vein-Eye ~~partnerships~~Carry ~~for~~is ~~IMTH~~lightweight and toportable ~~make~~and ~~IMTH~~can anbe ~~active~~successfully ~~sales~~carried ~~representative~~into toa ~~the~~home, ~~largest~~up ~~consumers~~flights of ~~wound care services~~stairs, ~~including~~carried ~~wound~~into ~~care~~a ~~centers,~~clinic nursing ~~homes~~home, ~~assisted~~placed ~~living~~in ~~centers~~an ambulance or another emergency medical vehicle. On December 15, ~~podiatrists~~2024, ~~etc.~~the ~~IMTH~~Company iswas ~~committed~~notified toby ~~becoming~~NII athat ~~major~~NII ~~player~~would inbe ~~advanced~~exercising ~~wound~~the ~~care~~thirty ~~treatment~~(30) notice for termination of the Agreement between the companies.

On or about May 17, 2024, the Company entered into an Exclusive License Agreement (the “Exclusive License Agreement”) with Shear Kershman Labs, a Missouri corporation (“SKL”). SKL has developed Oral Thrush, a mouth wash that treats oral thrush, a condition in which a fungus, Candida albicans, accumulates on the lining of the mouth and sometimes overgrows and causes symptoms, such as creamy white lesions, usually on the tongue or inner cheeks. Under the Exclusive License Agreement, SKL will form a subsidiary to distribute Oral Thrush, the Company shall become an 80% owner of the subsidiary, and the Company issued 2,000,000 shares of the Company’s Common Stock to SKL.

On December 20, 2024, Texas A&M University College of Dentistry and SKL signed a Memorandum of Understanding (MOU) to collaborate on transformative healthcare initiatives in oral care, including performing a bioequivalency study for Oral Thrush.

The Company is actively planning to sell its wholly-owned subsidiaries Sarah Adult Day Services, Inc., and Sarah Day Care Centers, Inc. Accordingly, the Company categorized Sarah Adult Day Services, Inc., and Sarah Day Care Centers, Inc. as discontinued operations in our financial statements for the three and six months ended December 31, 2024 and 2023.

Table of Contents

NOTE 2. LIQUIDITY, CAPITAL RESOURCES AND GOING CONCERN

The accompanying consolidated financial statements have been prepared on a going-concern basis, which contemplates the continuation of operations, realization of assets and liquidation of liabilities in the ordinary course of business.

For the ~~six~~nine months ended ~~December~~March 31, ~~2024~~2025 and ~~2023~~2024, the Company reported a net loss of $2,~~007~~096,~~864~~614 and $~~353~~1,~~208~~150,643, respectively.

As of ~~December~~March 31, ~~2024~~2025, the Company maintained total assets of $1,~~132~~063,~~186~~216, total liabilities including long-term debt of $5,~~976~~955,~~654~~434 along with an accumulated deficit of $46,~~569~~657,~~074~~824.

The Company continues to have limited capital resources and has experienced net losses and negative cash flows from operations and expects these conditions to continue for the foreseeable future. As of ~~December~~March 31, ~~2024~~2025, the Company had $98351 cash available for operations and had an accumulated deficit of $46,~~569~~657,~~074~~824. Management believes that cash on hand as of ~~December~~March 31, ~~2024~~2025 is not sufficient to fund operations through June 30, 2025. The Company will be required to raise additional funds to meet its short and long-term planned goals. There can be no assurance that such funds, if available at all, can be obtained on terms reasonable to the Company.

The Company believes that additional capital will be required to fund operations through June 30, 2025 and beyond, as it attempts to generate increasing revenue, and develop new products. The Company intends to attempt to raise capital through additional equity offerings and debt obligations. There can be no assurance that the Company will be successful in obtaining financing at the level needed or on terms acceptable to the Company. These conditions raise substantial doubt about the Company’s ability to continue as a going concern. The accompanying consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.

NOTE 3. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Basis of Presentation

The accompanying consolidated financial statements have been prepared in accordance with generally accepted accounting principles (“GAAP”) and pursuant to the rules and regulations of the Securities and Exchange Commission (the “SEC”) and reflect all adjustments, consisting of normal recurring adjustments, which management believes are necessary to fairly present the financial position, results of operations and cash flows of the Company as of and for the ~~six~~three and nine months ended ~~December~~March 31, ~~2024~~2025 and ~~2023~~2024. The ~~six~~nine months are not indicative of the year that will be ending June 30, 2025.

Principles of Consolidation

The Company has two wholly-owned operating subsidiaries; Sarah Adult Day Services, Inc., and Sarah Day Care Centers, Inc., along with non-operating subsidiaries consisting of the 6 formed limited liability companies formed for the additional SarahCare location leases. The consolidated financial statements, which include the accounts of the Company and its two wholly-owned subsidiaries, are prepared in conformity with GAAP pursuant to the rules and regulations of the SEC. All significant intercompany balances and transactions have been eliminated. The consolidated financial statements have been prepared using the accrual basis of accounting in accordance with GAAP and presented in US dollars. The fiscal year end is June 30.

Discontinued Operations

A component of an entity that is disposed of by sale or abandonment is reported as discontinued operations if the transaction represents a strategic shift that will have a major effect on an entity's operations and financial results. The results of discontinued operations are aggregated and presented separately in the Consolidated Statement of Operations. Assets and liabilities of the discontinued operations are aggregated and reported separately as assets and liabilities of discontinued operations in the Consolidated Balance Sheet, including the comparative prior year period. Sarah Adult Day Services, Inc., and Sarah Day Care Centers, Inc. cash flows are reflected as cash flows from discontinued operations within the Company’s Consolidated Statements of Cash Flows for each period presented.

Table of Contents

Discontinued Operations

A component of an entity that is disposed of by sale or abandonment is reported as discontinued operations if the transaction represents a strategic shift that will have a major effect on an entity’s operations and financial results. The results of discontinued operations are aggregated and presented separately in the Consolidated Statement of Operations. Assets and liabilities of the discontinued operations are aggregated and reported separately as assets and liabilities of discontinued operations in the Consolidated Balance Sheet, including the comparative prior year period. Sarah Adult Day Services, Inc., and Sarah Day Care Centers, Inc. cash flows are reflected as cash flows from discontinued operations within the Company’s Consolidated Statements of Cash Flows for each period presented.

Amounts presented in discontinued operations have been derived from our consolidated financial statements and accounting records using the historical basis of assets, liabilities, and historical results of Sarah Adult Day Services, Inc., and Sarah Day Care Centers, Inc. The discontinued operations exclude general corporate allocations.

Use of Estimates

The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported revenues and expenses during the reporting periods. Because of the use of estimates inherent in the financial reporting process, actual results may differ significantly from those estimates.

Cash and Cash Equivalents

The Company maintains cash balances in a non-interest-bearing account that does not exceed $250,000 at ~~December~~March 31, ~~2024~~2025. For the purpose of the consolidated financial statements, all highly liquid investments with a maturity of three months or less are considered to be cash equivalents. There were no cash equivalents as of ~~December~~March 31, ~~2024~~2025 and ~~2023~~2024.

Earnings Per Share Calculation

Basic earnings per common share (“EPS”) is computed by dividing income available to common stockholders by the weighted-average number of common shares outstanding for the period. Diluted earnings per share is computed by dividing net income by the weighted average shares outstanding, assuming all dilutive potential common shares were issued. There are 141,~~084~~602,~~366,651~~427 of Common Stock Equivalents (“CSE”) not included in the diluted per share because they are considered anti-dilutive.

Revenue Recognition

Revenue is recognized when a customer obtains services. The amount of revenue that is recorded reflects the consideration that the Company expects to receive in exchange for those goods. The Company applies the following five-step model in order to determine this amount: (i) identification of the promised goods in the contract; (ii) determination of whether the promised goods are performance obligations, including whether they are distinct in the context of the contract; (iii) measurement of the transaction price, including the constraint on variable consideration; (iv) allocation of the transaction price to the performance obligations; and (v) recognition of revenue when (or as) the Company satisfies each performance obligation.

The Company only applies the five-step model to contracts when it is probable that the entity will collect the consideration it is entitled to in exchange for the services it provides to the customer. Once a contract is determined to be within the scope of Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 606 at contract inception, the Company reviews the contract to determine which performance obligations the Company must deliver and which of these performance obligations are distinct.

This is now presented in the Gain (Loss) of discontinued operations on the Unaudited Consolidated Statement of Operations.

Patient Fees

Participant fee revenue is reported at the amount that reflects the consideration the Company expects to receive in exchange for the services provided. These amounts are due from participants or third-party payors and include variable consideration for retroactive adjustments from estimated reimbursements, if any, under reimbursement programs. Performance obligations are determined based on the nature of the services provided. Resident fee revenue is recognized as performance obligations are satisfied.

Under the Company’s day care agreements, which are generally for a contractual term of 30 days to one year, the Company provides services to participants for a stated daily or monthly fee. The Company has elected the lessor practical expedient within ASC 842, Leases (“ASC 842”) and recognizes, measures, presents, and discloses the revenue for services under the Company’s senior living residency agreements based upon the predominant component, either the lease or nonlease component, of the contracts. The Company has determined that the services included under the Company’s independent living, assisted living, and memory care residency agreements have the same timing and pattern of transfer and are performance obligations that are satisfied over time. The Company recognizes revenue under ASC 606, Revenue Recognition from Contracts with Customers (“ASC 606”) for its participants agreements for which it has estimated that the nonlease components of such agreements are the predominant component of the contract.

Table of Contents

Under the Company’s day care agreements, which are generally for a contractual term of 30 days to one year, the Company provides services to participants for a stated daily or monthly fee. The Company has elected the lessor practical expedient within ASC 842, Leases (“ASC 842”) and recognizes, measures, presents, and discloses the revenue for services under the Company’s senior living residency agreements based upon the predominant component, either the lease or nonlease component, of the contracts. The Company has determined that the services included under the Company’s independent living, assisted living, and memory care residency agreements have the same timing and pattern of transfer and are performance obligations that are satisfied over time. The Company recognizes revenue under ASC 606, Revenue Recognition from Contracts with Customers (“ASC 606”) for its participants agreements for which it has estimated that the nonlease components of such agreements are the predominant component of the contract.

The Company enters into contracts to provide home assisted health, and certain outpatient services. Each service provided under the contract is capable of being distinct, and thus, the services are considered individual and separate performance obligations. The performance obligations are satisfied as services are provided and revenue is recognized as services are provided.

The Company receives payment for services under various third-party payor programs which include Medicaid, Veterans Affairs and other third-party payors. Estimates for settlements with third-party payors for retroactive adjustments from estimated reimbursements due to audits, reviews, or investigations are included in the determination of the estimated transaction price for providing services. The Company estimates the transaction price based on the terms of the contract with the payor, correspondence with the payor, and historical payment trends. Changes to these estimates for retroactive adjustments are recognized in the period the change or adjustment becomes known or when final settlements are determined.

Billings for services under third-party payor programs are recorded net of estimated retroactive adjustments, if any. Retroactive adjustments are accrued on an estimated basis in the period the related services are rendered and adjusted in future periods or as final settlements are determined. Contractual or cost related adjustments from Medicaid or Veterans Affairs are accrued when assessed (without regard to when the assessment is paid or withheld). Subsequent adjustments to these accrued amounts are recorded in net revenues when known.

This is now presented in the Gain (Loss) of discontinued operations on the Unaudited Consolidated Statement of Operations.

Franchise Fees

The Company franchises a number of its locations under franchise contracts which provide periodic franchise fee payments to the Company and reimbursement for costs and expense related to such franchises. The Company’s franchisees pay a variety of royalties and fees, including an agreed upon percentage of gross revenues (as defined in the franchise agreement). The Company estimates the amount of franchise fee revenue expected to be earned, if any, during the annual contract period and revenue is recognized as services are provided. The Company’s estimate of the transaction price for the franchise services also includes the amount of reimbursement due from the franchises for services provided and related costs incurred.

SarahCare, as the franchisor, supplies the franchisee’s with initial assistance and approval with the following: (1) Providing the site selection criteria for the SARAH Business and, upon a potential franchisee’s request, provide input regarding possible sites. The Company does not own and lease any site to franchisees. After the franchise selects and the Company approves a site, the Company will designate the geographic area within which they may establish the SARAH Business; (2) Approve the signage; (3) Identify the standards and specifications for products, services, and materials that comply with the System, and, if the Company requires, the approved suppliers of these items. The Company will furnish a potential Franchisee with the listing of the package of initial franchise items as detailed in the Operations Manual. Neither the Company or its affiliate provide, deliver, or install any of these items; (4) Provide an Initial Training Program; and (5) Provide an Operations Training Program.

Once the Franchisee’s SarahCare business is operational, the Company will: (1) Issue and modify System standards for SARAH Businesses; (2) Provide access to a copy of the Company’s Operations Manual as they make available through our intranet. The Operations Manual contains mandatory and suggested specifications, standards and operating procedure; (3) Provide additional or special guidance and assistance and training as the Company deem appropriate and for which a potential Franchisee are financially responsible; (4) Inspect and observe the operation of the SARAH Business to help a potential Franchisee comply with the Franchise Agreement and all System standards; (5) Let the Franchisee use the confidential information; and, (6) Let the Franchisee use the Marks (trademarks, trade names, service marks, and logos).

Table of Contents

This is now presented in the Gain (Loss) of discontinued operations on the Unaudited Consolidated Statement of Operations.

Income Taxes

The provision for income taxes is the total of the current taxes payable and the net of the change in the deferred income taxes. Provision is made for the deferred income taxes where differences exist between the period in which transactions affect current taxable income and the period in which they enter into the determination of net income in the financial statements.

Leases

The Company accounts for leases in accordance with Accounting Standards Update (ASU) 2016-02, “Leases” (Topic 842). Based on this standard, the Company determines if an agreement is a lease at inception. Leases are included – right to use, current portion of lease liability, and operating lease liability, less current portion in the Company’s consolidated balance sheets. Finance leases are included in property, plant and equipment, net current portion of long-term debt, net and long-term debt, less current portion and debt issuance costs in the Company’s consolidated balance sheets.

Fair value of financial instruments

The Company’s financial instruments include cash and cash equivalents, accounts payable, accrued expenses, and debt. The carrying value of these financial instruments is considered to be representative of their fair value due to the short maturity of these instruments. The carrying amount of the debt approximates fair value, because the interest rates on these instruments approximate the interest rate on debt with similar terms available to the Company. The Company’s derivative liabilities were adjusted to fair market value at the end of each reporting period, using Level 3 inputs.

Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability, in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. The fair value hierarchy is based on three levels of inputs, of which the first two are considered observable and the last unobservable, as follows:

Level 1 – Quoted prices in active markets for identical assets or liabilities.

Level 2 – Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.

Level 3 – Unobservable inputs that are supported by little or no market activity and that are significant to the measurement of the fair value of the assets or liabilities.

The carrying amounts of the Company’s financial assets and liabilities, such as cash, accounts payable, accrued expenses and interest, certain notes payable and notes payable – due to related parties, approximate their fair values because of the short maturity of these instruments. The Company accounts for its derivative liabilities, at fair value, on a recurring basis under Level 3 (See Note 11).

Embedded Conversion Features

The Company evaluates embedded conversion features within convertible debt under ASC 815 “Derivatives and Hedging” to determine whether the embedded conversion feature(s) should be bifurcated from the host instrument and accounted for as a derivative at fair value with changes recorded in earnings. If the conversion feature does not require derivative treatment under ASC 815, the instrument is evaluated under ASC 470-20 “Debt with Conversion and Other Options” for consideration of any beneficial feature.

Table of Contents

Derivative financial instruments

When the Company issues debt that contains a conversion feature, it first evaluates whether the conversion feature meets the requirements to be treated as a derivative: a) one or more underlying, typically the price of the Company’s stock; b) one or more notional amounts or payment provisions or both, generally the number of shares upon conversion; c) no initial net investment, which typically excludes the amount borrowed; and d) net settlement provisions, which in the case of convertible debt generally means the stock received upon conversion can be readily sold for cash. There are certain scope exceptions from derivative treatment, but these typically exclude conversion features that provide for a variable number of shares.

If the conversion features within convertible debt meet the requirements to be treated as a derivative, the Company estimates the fair value of the derivative liability using the Monte Carlo Simulation Model upon the date of issuance. If the fair value of the derivative liability is higher than the face value of the convertible debt, the excess is immediately recognized as interest expense. Otherwise, the fair value of the derivative liability is recorded as a liability with an offsetting amount recorded as a debt discount, which offsets the carrying amount of the debt. The derivative liability is revalued at the end of each reporting period and any change in fair value is recorded as a change in fair value in the consolidated statements of operations. The debt discount is amortized through interest expense over the life of the debt. Derivative instrument liabilities and the host debt agreement are classified on the consolidated balance sheets as current or non-current based on whether settlement of the derivative instrument could be required within twelve months of the balance sheet date.

The accounting treatment of derivative financial instruments requires that the Company record the embedded conversion option at their fair values as of the inception date of the agreement and at fair value as of each subsequent balance sheet date. Any change in fair value is recorded as non-operating, non-cash income or expense for each reporting period at each balance sheet date. The Company reassesses the classification of its derivative instruments at each balance sheet date. If the classification changes as a result of events during the period, the contract is reclassified as of the date of the event that caused the reclassification. As a result of entering into warrant agreements, for which such instruments contained a variable conversion feature with no floor, the Company has adopted a sequencing policy in accordance with ASC 815-40-35-12 “Derivatives and Hedging” (provides comprehensive guidance on derivative and hedging transactions) whereby all future instruments may be classified as a derivative liability with the exception of instruments related to share-based compensation issued to employees or directors.

Debt Issue Costs and Debt Discount

The Company may record debt issue costs and/or debt discounts in connection with raising funds through the issuance of debt. These costs may be paid in the form of cash, or equity (such as warrants). These costs are amortized to interest expense over the life of the debt. If a conversion of the underlying debt occurs, a proportionate share of the unamortized amounts is immediately expensed.

Reclassification of Presentation

Certain prior year amounts have been reclassified to conform with current year presentation. These reclassifications had no effect on the reported results of operations.

Recently Issued Accounting Pronouncements

In November 2023, the FASB issued ASU 2023-07, *Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures*, enhancing segment expense transparency. The update requires public entities to disclose significant segment expenses regularly provided to the chief operating decision maker and extends certain annual segment disclosures to interim periods. ASU 2023-07 is effective for fiscal years beginning after December 15, 2023, with interim period application required starting after December 15, 2024, and early adoption permitted.

The Company does not expect any of the recently issued accounting pronouncements to have a material impact on its financial condition or results of operations for the quarter ended as of ~~December~~March 31, ~~2024~~2025 or on a going forward basis.

Subsequent Events

In accordance with ASC 855, Subsequent Events, the Company evaluated subsequent events through the date of this report; the date the consolidated financial statements were available for issue.

Table of Contents

NOTE 4. SEGMENT REPORTING

The Company operates as a single reportable segment and evaluates performance based on revenue and operating income. In accordance with ASU 2023-07, the Company discloses significant segment expenses that are regularly provided to the chief operating decision maker (CODM) and included in the reported measure of segment profit. For the period ended ~~December~~March 31, ~~2024~~2025, significant segment expenses include consulting fees and stock based compensation.

Since the Company has only one reportable segment, all required segment disclosures, including those previously presented only on an annual basis, are now provided in both annual and interim financial statements.

NOTE 5. DISCONTINUED OPERATIONS

The operating results for discontinued operations have been presented in the accompanying consolidated statement of operations for the ~~six~~nine months ended ~~December~~March 31, ~~2024~~2025 and ~~2023~~2024 as discontinued operations and are summarized below:

	Six Months EndedDecember 31,
	Nine Months Ended March 31,
	2024			2023
	2025			2024
Total revenue	$	~~843~~1,~~080~~274,081		$	~~913~~1,~~399~~368,564
Operating expenses		~~793~~1,~~441~~185,764			1,~~025~~517,~~730~~707
Income from operations		4988,~~639~~317			(~~112~~149,~~331~~143	)
Other income (expenses)		(717,~~154~~072	)		4436,~~661~~706
Gain (loss) from operations of discontinued operations	$	4271,~~485~~245		$	(67112,~~670~~437	)

The operating results for discontinued operations have been presented in the accompanying consolidated statement of operations for the three months ended ~~December~~March 31, ~~2024~~2025 and ~~2023~~2024 as discontinued operations and are summarized below:

	Three Months EndedDecember 31,
	Three Months Ended March 31,
	2024			2023
	2025			2024
Total revenue	$	~~414~~431,~~696~~017		$	~~432~~455,~~691~~165
Operating expenses		~~435~~392,~~810~~348			~~495~~491,~~612~~977
Income from operations		~~(21~~38,~~114~~669	)		(6236,~~921~~812	)
Other income (expenses)		5(9,~~821~~909	)		4(7,~~693~~955	)
Gain (loss) from operations of discontinued operations	$	~~(15~~28,~~293~~760	)	$	(5844,~~228~~767	)

Table of Contents

The assets and liabilities of the discontinued operations at ~~December~~March 31, ~~2024~~2025 and June 30, 2024 are summarized below:

		December 31,2024		June 30,2024
		March 31, 2025		June 30, 2024
Cash and cash equivalents		$	8864,~~663~~076	$	112,615
Accounts receivable, net			~~155~~169,~~433~~814		160,997
Prepaid expenses			126,~~404~~851		0-
Assets of discontinued operations, current			~~256~~240,~~500~~741		273,612
Deposits			7,~~962~~961		7,962
Right-of-use asset	(2)		~~206~~161,~~105~~390		241,210
Finance lease asset, net	(2)		8,~~780~~033		11,475
Property and equipment, net	(1)		~~102~~94,~~647~~646		107,455
Assets of discontinued operations, non-current			~~325~~272,~~494~~030		368,102
Total Assets		$	~~581~~512,~~994~~771	$	641,714
Accounts payable and accrued expenses		$	~~892~~879,~~243~~527	$	896,673
Accrued interest			14,902		14,902
Accrued interest, related parties			5963,~~558~~521		51,633
Notes payable, related parties, current	(3)		158,502		158,502
Notes payable, current	(4)		3831,~~687~~465		46,664
SBA loan	(5)		67,~~958~~023		5,359
Line of credit			4544,~~448~~539		72,810
Finance lease liability	(2)		2829,~~869~~413		27,809
Operating lease liability	(2)		~~117~~98,~~706~~564		144,182
Liabilities of discontinued operations, current			1,~~362~~327,~~873~~456		1,418,534
Notes payable, non-current			4942,~~892~~752		66,999
Finance lease liability, non-current			3123,~~110~~550		45,814
Operating lease liability, non-current			9368,~~570~~002		97,884
SBA Loan, non-current			~~310~~305,~~714~~411		322,789
Liabilities of discontinued operations, non-current			~~485~~439,~~286~~715		533,486
Total Liabilities		$	1,~~848~~767,~~159~~171	$	1,952,020

Table of Contents

(1) Property and equipment, net

Property and equipment, at cost, for the discontinued operations consisted of the following at ~~December~~March 31, ~~2024~~2025 and June 30, 2024:

	December 31,			June 30,
	March 31,			June 30,
	2024			2024
	2025			2024
Leasehold improvements	$	20,077		$	20,077
Vehicles		130,135			130,135
Computer equipment		25,048			13,493
Furniture and fixtures		3,046			3,046
		178,306			166,751
Less: Accumulated depreciation		(7583,~~659~~660	)		(59,296	)
Property, plant and equipment - net	$	~~102~~94,~~647~~646		$	107,455

Depreciation expense for the discontinued operations for the ~~six~~nine months ended ~~December~~March 31, ~~2024~~2025 and ~~2023~~2024 was $1926,~~715~~992 and $3036,~~652~~583, respectively.

Depreciation expense for the discontinued operations for the three months ended ~~December~~March 31, ~~2024~~2025 and ~~2023~~2024 was $78,~~840~~001 and $1016,~~904~~568, respectively.

(2) Leases

Operating leases

Stow Professional Lease

Sarah Adult Day Centers, Inc. has a facilities lease with 6,000 square feet at 4472 Darrow Road, Stow, Ohio 44224. The lease ~~expires~~expired on ~~December~~March 31, 2025 and the lease payments are as follows:

	Monthly Rent Payments
	Base Rent		Covid-19Recoup*		Total Rent
April 1, 2021	$	6,369	$	983	$	7,352
May 1, 2021 to December 31, 2021	$	6,369	$	621	$	6,990
May 1, 2021 to March 31, 2021	$	6,369	$	621	$	6,990
January 1, 2022 to December 31, 2022	$	6,433	$	621	$	7,054
January 1, 2022 to March 31, 2022	$	6,433	$	621	$	7,054
January 1, 2023 to December 31, 2023	$	6,497	$	621	$	7,118
January 1, 2023 to March 31, 2023	$	6,497	$	621	$	7,118
January 1, 2024 to December 31, 2024	$	6,562	$	621	$	7,183
January 1, 2024 to March 31, 2024	$	6,562	$	621	$	7,183
January 1, 2025 to December 31, 2025	$	6,628	$	621	$	7,249
January 1, 2025 to March 31, 2025	$	6,628	$	621	$	7,249

________

*The Company has to repay the lessor monthly payments as a result of COVID relief.

17 Table of Contents

Harbor Lease

Sarah Adult Day Centers, Inc. has a facilities lease with 3,469 square feet at 4580 Stephen Circle NW. Canton, OH 44718. The monthly lease payments are $4,500 and the lease expires on December 31, 2023.

Sarah Day Care Centers, Inc. on March 25, 2021, the Company acquired a facilities lease with 5,300 square feet in Jackson, Ohio. The monthly lease payments are $7,910, which includes monthly payments of $603 as repayments for COVID relief. The lease expires on July 1, 2026.

S. Frank Professional Lease

Higbee Lease

Sarah Adult Day Centers, Inc. has a facilities lease with 3,469 square feet at 4580 Stephen Circle NW. Canton, OH 44718. The monthly lease payments are $1,245 and the lease expires on as of October 15, 2028.

Table of Contents

Operating lease right-of-use asset and liability are recognized at the present value of the future lease payments at the lease commencement date. The interest rate used to determine the present value is the incremental borrowing rate, estimated to be 10%, as the interest rate implicit in most of the Company’s leases is not readily determinable. Operating lease expense is recognized on a straight-line basis over the lease term. Since the common area maintenance expenses are expenses that do not depend on an index or rate, they are excluded from the measurement of the lease liability and recognized in general and administrative expenses on the consolidated statements of operations.

Right-of-use asset is summarized below:

	December 31, 2024
	March 31, 2025
	Stow Professional Center Lease			S. ~~FrankProfessional~~Frank Professional Lease			Higbee Lease			Total
Office lease	$	282,371		$	412,770		$	60,115		$	755,256
Less: accumulated amortization		(~~261~~282,~~222~~371	)		(~~273~~293,~~147~~756	)		(1417,~~782~~739	)		(~~549~~593,~~151~~866	)
Right-of-use asset, net	$	~~21,149~~-		$	~~139~~119,~~623~~014		$	4542,~~333~~376		$	~~206~~161,~~105~~390

Right-of-use asset is summarized below:

	June 30, 2024
	Stow Professional Center Lease			S. ~~FrankProfessional~~Frank Professional Lease			Total
Office lease	$	282,371		$	412,770		$	695,141
Less: accumulated amortization		(220,493	)		(233,438	)		(453,931	)
Right-of-use asset, net	$	61,878		$	179,332		$	241,210

Operating lease liability is summarized below:

December 31, 2024

March 31, 2025

Stow Professional Center Lease

S. ~~FrankProfessional~~Frank Professional Lease

Higbee Lease

Total

Office lease

~~21,565~~-

~~139~~119,~~623~~014

5047,~~088~~552

~~211~~166,~~276~~566

Less: current portion

~~(21,565~~-

)

(8587,~~605~~764

)

(10,~~536~~800

)

(~~117~~98,~~706~~564

)

Long term portion

5431,~~018~~250

3936,~~552~~752

9368,~~570~~002

18 Table of Contents

Operating lease liability is summarized below:

	June 30, 2024
	Stow Professional Center Lease			S. ~~FrankProfessional~~Frank Professional Lease			Total
Office lease	$	62,733		$	179,333		$	242,066
Less: current portion		(62,733	)		(81,449	)		(144,182	)
Long term portion	$	-		$	97,884		$	97,884

Table of Contents

Maturity of the lease liability is as follows:

Finance leases

	December 31, 2024
	March 31, 2025
	Stow Professional Center Lease			S. ~~FrankProfessional~~Frank Professional Lease			Higbee Lease			Total
Year ending June 30, 2025	$	~~21,745~~-		$	4723,~~462~~731		$	73,~~472~~736		$	7627,~~679~~467
Year ending June 30, 2026		-			94,923			14,944			109,867
Year ending June 30, 2027		-			7,910			15,941			23,851
Year ending June 30, 2028		-			-			16,440			16,440
Year ending June 30, 2029		-			-			5,480			5,480
Total future minimum lease payments		~~21,745~~-			~~150~~126,~~295~~564			6056,~~277~~541			~~232~~183,~~317~~105
Present value discount		~~(180~~-	)		(107,~~672~~550	)		(108,~~191~~989	)		(2116,~~043~~539	)
Lease liability	$	~~21,565~~-		$	~~139~~119,~~623~~014			5047,~~086~~552		$	~~211~~166,~~274~~566

Commencing during the ~~six~~nine months ended ~~December~~March 31, ~~2024~~2025, the Company leases office equipment under two finance leases with combined monthly payments of $5,897. The leases mature on March 1, ~~2024~~2025 and December 1, 2026.

Finance right of use assets are summarized below:

	As of			As of
	December 31,			June 30,
	March 31,			June 30,
	2024			2024
	2025			2024
Equipment lease	$	24,097		$	24,097
Less accumulated amortization		(1516,~~317~~064	)		(12,622	)
Finance right of use asset	$	8,~~780~~033		$	11,475

~~On October 1, 2021, the Company discontinued use of one of its copiers. As a result, the Company recorded an impairment of assets in the amount of $84,364.~~ Amortization expense was $13,~~108~~442 and $5,738 for the ~~six~~nine months ended ~~December~~March 31, ~~2024~~2025 and ~~2023~~2024, respectively.

19 Table of Contents

Finance lease liabilities are summarized below:

	As of			As of
	December 31,			June 30,
	March 31,			June 30,
	2024			2024
	2025			2024
Equipment lease	$	5952,~~979~~963		$	73,623
Less: current portion		(2829,~~869~~413	)		(27,809	)
Long term portion	$	3123,~~110~~550		$	45,814

	Equipment
	Lease
Year Ended June 30, 2025	$	168,~~194~~097
Year Ended June 30, 2026		32,388
Year Ended June 30, 2027		16,194
Total future minimum lease payments		6456,~~776~~679
Less imputed interest		(43,~~798~~716	)
PV of payments	$	5952,~~978~~963

Table of Contents

(3) Notes payable, related parties

As of ~~December~~March 31, ~~2024~~2025 and June 30, 2024, the Company had $158,502 in outstanding notes payable, related parties. As of ~~December~~March 31, ~~2024~~2025 and June 30, 2024, the Company had $5963,~~558~~531 and $51,633, respectively, in accrued interest related to these notes.

Ref No. Note			Date of	Original Principal		Maturity	Interest			Principal		Principal
Issuance			Issuance	~~Rate %~~		Date	Rate %			Balance 123/31/2425		Balance 6/30/24
	1	*	3/25/21		158,502	~~6/3/21~~*		10	%	$	158,502	$	158,502
			Total							$	158,502	$	158,502

* As of March 31, 2025, this note is in default.

(4) Notes payable

As of ~~December~~March 31, ~~2024~~2025 and June 30, 2024, the Company had $~~388~~74,~~864~~217 and $~~263~~113,~~931~~663, respectively, in outstanding notes payable, as following:

			Original					Principal Balance as of
		Date of Note	Principal		Maturity	Interest		~~December~~March 31,		June 30,
Ref No.		Issuance	Balance		Date	Rate (%)		~~2024~~2025		2024
	1	12/25/20	$	146,021	08/15/2025		10	$	2213,~~041~~776	$	38,572
	2	26/2415/1423		90,985	05/05/2028		9		6660,~~538~~441		75,091
		Total						$	8874,~~579~~217	$	113,663
		Total Current						$	3831,~~687~~465	$	46,664
		Total Long Term						$	4942,~~892~~752	$	66,999

(5) SBA loan

On June 25, 2020 and January 6, 2022, Sarah Day Care Centers, Inc. received proceeds of $150,000 and $200,000, respectively, in the form of an SBA loan. Installment payments, including principal and interest of $1,746 are due monthly beginning on December 22, 2021. The balance of principal and interest is payable thirty years from the promissory note date. The interest accrues at a rate of 3.75% per annum. During the ~~six~~three months ended ~~December~~March 31, ~~2024~~2025 and ~~2023~~2024, the Company recorded $03,147 and $3,273 in interest expense related to the SBA loan. During the nine months ended March 31, 2025 and 2024, the Company recorded $9,491 and $9,597 in interest expense related to the SBA loan.

	Amount Owed

Year Ended June 30, 2025	$	3,446
Year Ended June 30, 2026		7,089
Year Ended June 30, 2027		7,360
Year Ended June 30, 2028		7,641
Year Ended June 30, 2029		7,932

Payments 2030 & Thereafter		284,204
Total Payments	$	317,672

Table of Contents

NOTE 6. NOTES RECEIVABLE, RELATED PARTIES

The Company has several notes receivables from a related party. They are as follows:

	December 31, 2024		June 30, 2024
	March 31, 2025		June 30, 2024
Notes receivable from related party due in three months, with no installments, no interest, and in default as of March 2022		9,294		9,294
Total notes receivable		9,294		9,294
Less long-term		-		-
Total short term notes receivable	$	9,294	$	9,294

NOTE 7. NOTES PAYABLE

As of ~~December~~March 31, ~~2024~~2025 and June 30, 2024, the Company had $~~388~~382,~~864~~526 and $263,931, respectively, in outstanding notes payable, as following:

			Original					Principal Balance as of
		Date of Note	Principal		Maturity	Interest		~~December~~March 31,			June 30,
~~Ref No.~~	Ref No.	Issuance	Balance		Date	Rate (%)		~~2024~~2025			2024
	1	9/16/06	$	100,000	*		12	$	38,000		$	38,000
	2	2/24/14		5,000	*		9		8,547			8,547
	3	2/24/14		39,000	*		9		33,687			33,687
	4	2/24/14		179,124	*		9		33,697			33,697
	5	8/21/23		150,000	*		12		148,000			150,000
	6	7/30/24		40,250	5/30/25		14		3925,~~629~~863			-
	7	7/30/24		51,750	5/30/25		12		3610,~~225~~350			-
	8	12/9/24		28,500	~~3/7/25~~*		12		28,500			-
	9	12/12/24		28,500	~~3/7/25~~*		12		28,500			-
	Less: Unamortized	discount							(5,921	)		-
	10	2/7/25		5,500	5/7/2025		12		5,500
		Total						$	388,864		$	263,931
	11	2/10/25		21,641	5/10/25		12		21,641			-
		Total Current						$	388,864		$	263,931
	12	Various		9,944	On Demand	NA			241			-
		Total Long Term						$	-		$	-
	Less: Unamortized	discount							-			-
		Total						$	382,526		$	263,931

________

* As of ~~December~~March 31, ~~2024~~2025, these notes are in default.

Table of Contents

On February 10, 2025, the Company entered into a Promissory Note Agreement with a lender in the amount of $21,641, at an interest rate of 12% and a maturity date of May 10, 2025.

On February 7, 2025, the Company entered into a Promissory Note Agreement with a lender in the amount of $5,500, at an interest rate of 12% and a maturity date of May 7, 2025.

On December 12, 2024, the Company entered into a Promissory Note Agreement with a lender in the amount of $28,500, at an interest rate of 12% and a maturity date of March 7, 2025.

On December 9, 2024, the Company entered into a Promissory Note Agreement with a lender in the amount of $28,500, at an interest rate of 12% and a maturity date of March 7, 2025.

On July 30, 2024, the Company entered into a Promissory Note Agreement with a lender in the amount of $40,250, at an interest rate of 14% and a maturity date of May 30, 2025. If the Company defaults, then the Notes have a conversion price at the lower of of $0.01 or a 29% discount to the lowest trading price for the 10 prior trading days to the conversion date.

On July 30, 2024, the Company entered into a Promissory Note Agreement with a lender in the amount of $51,750, at an interest rate of 12% and a maturity date of May 30, 2025. If the Company defaults, then the Notes have a conversion price at the lower of of $0.01 or a 29% discount to the lowest trading price for the 10 prior trading days to the conversion date.

NOTE 8. NOTES PAYABLE, RELATED PARTIES

As of ~~December~~March 31, ~~2024~~2025 and June 30, 2024, the Company had $674,271 and $674,271 respectively, in outstanding notes payable, related parties. As of ~~December~~March 31, ~~2024~~2025 and June 30, 2024, the Company had $~~240~~192,~~994~~847 and $203,711, respectively, in accrued interest related to these notes. Some of these notes were assumed in connection with the acquisition on March 25, 2021.

Ref No. Note			Date of	Original Principal		Maturity	Interest			Principal		Principal
Issuance			Issuance	Rate %		Date	Rate %			Balance 123/31/2425		Balance 6/30/24
	1	*	3/25/21		308,500	6/3/21		10	%	$	308,501	$	308,501
	2	*	3/25/21		47,436	6/3/21		10	%		47,436		47,436
	4	*	3/24/22		39,000	9/24/22		6	%		39,000		39,000
	5	*	5/5/22		179,124	11/5/22		6	%		179,124		179,124
	6	*	10/5/22		20,000	4/5/23		6	%		20,000		20,000
	7	*	11/9/22		500	5/9/23		6	%		500		500
	8	*	11/18/22		4,000	5/18/23		6	%		4,000		4,000
	9	*	1/17/23		18,000	7/17/23		6	%		18,000		18,000
	10	*	2/8/23		27,000	8/8/23		6	%		27,000		27,000
	11	*	4/28/23		650	10/28/23		6	%		650		650
	12	*	5/16/23		900	11/16/23		6	%		900		900
	13	*	5/30/23		875	11/30/23		6	%		875		875
	14	*	5/21/23		410	11/31/23		6	%		410		410
	15	*	6/29/23		875	12/29/23		6	%		875		875
	16	*	1/12/24		5,000	7/12/24		6	%		5,000		5,000
	17	*	1/16/24		7,000	7/16/24		6	%		7,000		7,000
	18	*	2/21/24		10,000	8/21/24		6	%		10,000		10,000
	19	*	4/1/24		5,000	10/1/24		6	%		5,000		5,000
			Total							$	674,271	$	674,271

* As of ~~December~~March 31, ~~2024~~2025, these notes are in default.

The above amounts and terms are not necessarily what third parties would agree to.

Table of Contents

The above amounts and terms are not necessarily what third parties would agree to.

NOTE 9. CONVERTIBLE NOTES PAYABLE

As of ~~December~~March 31, ~~2024~~2025 and June 30, 2024, the convertible notes payable were as follows:

Date of NoteIssuance	Original Principal Balance		Maturity Date	Interest Rate %			Conversion Rate		PrincipalBalance 123/31/2425		PrincipalBalance 6/30/24
8/26/14		50,000	*		10	%	$	0.0001	$	50,000	$	50,000
6/15/12		8,000	*		10	%	$	0.000350		8,000		8,000
10/18/11		1,900	*		8	%	25% discount to market			6,900		6,900
10/3/10		20,000	*		10	%	lesser $0.01 or 20% discount to market			20,000		20,000
10/31/09		4,000	*		8	%	25% discount of previous 5 days closing price			4,000		4,000
2/26/07		30,000	*		12	%	lesser $0.50 or 35% discount to market			30,000		30,000
4/17/07		20,000	*		10	%	lesser $0.45 or 35% discount to market			20,000		20,000
6/14/07		15,000	*		10	%	lesser $0.50 or 25% discount to market			15,000		15,000
1/29/07		15,000	*		10	%	$	0.95		15,000		15,000
4/17/07		15,000	*		10	%	lesser $0.45 or 35% discount to market			15,000		15,000
12/23/06		18,000	*		10	%	$	0.95		18,000		18,000
11/30/06		50,000	*		10	%	$	0.85		50,000		50,000
10/1/05		15,000	*		10	%	$	0.50		15,000		15,000
Total Current									$	266,900	$	266,900

* As of ~~December~~March 31, ~~2024~~2025, these notes are in default.

Table of Contents

NOTE 10. DERIVATIVE FINANCIAL INSTRUMENTS

The following tables summarize the components of the Company’s derivative liabilities and linked common shares.

	December 31, 2024
	March 31, 2025
	Indexed		Fair
The financings giving rise to derivative financial instruments	Shares		Values
Compound embedded derivative		1,~~066~~102,~~032~~427	$	~~201~~202,~~292~~550

	June 30, 2024
	Indexed		Fair
The financings giving rise to derivative financial instruments	Shares		Values
Compound embedded derivative		818,753	$	193,557

The following tables summarizes the effects on the Company’s gain (loss) associated with changes in the fair values of the derivative financial instruments by type of financing for the three and ~~six~~nine months ended ~~December~~March 31, ~~2024~~2025 and ~~2023~~2024:

The financings giving rise to derivative financial instruments and the income effects:

	Three Months Ended
	Nine Months Ended
	December 31,			December 31,
	March 31,			March 31,
	2024			2023
	2025			2024
Compound embedded derivative	$	(18,~~292~~993	)	$	530,~~165~~779
Day one derivative loss		-			-
Total derivative gain (loss)	$	(18,~~292~~993	)	$	530,~~165~~779

	Six Months Ended
	Three Months Ended
	December 31,			December 31,
	March 31,			March 31,
	2024			2023
	2025			2024
Compound embedded derivative	$	(71,~~735~~258	)	$	~~(19~~11,~~568~~211	)
Day one derivative loss		-			-
Total derivative gain (loss)	$	(71,~~735~~258	)	$	~~(19~~11,~~568~~211	)

The Company’s convertible notes gave rise to derivative financial instruments. The notes embodied certain terms and conditions that were not clearly and closely related to the host debt agreement in terms of economic risks and characteristics. These terms and features consist of the embedded conversion option.

Current accounting principles that are provided in ASC 815 – Derivatives and Hedging require derivative financial instruments to be classified in liabilities and carried at fair value with changes recorded in income. In addition, the standards do not permit an issuer to account separately for individual derivative terms and features embedded in hybrid financial instruments that require bifurcation and liability classification as derivative financial instruments. Rather, such terms and features must be bundled together and fair valued as a single, compound embedded derivative. The Company has selected the Monte Carlo Simulations valuation technique to fair value the compound embedded derivative because it believes that this technique is reflective of all significant assumption types, and ranges of assumption inputs, that market participants would likely consider in transactions involving compound embedded derivatives. Such assumptions include, among other inputs, interest risk assumptions, credit risk assumptions and redemption behaviors in addition to traditional inputs for option models such as market trading volatility and risk-free rates. The Monte Carlo Simulations technique is a level three valuation technique because it requires the development of significant internal assumptions in addition to observable market indicators.

Table of Contents

Significant inputs and results arising from the Monte Carlo Simulations process are as follows for the compound embedded derivative that has been bifurcated from the Convertible Notes and classified in liabilities:

	Inception			~~December~~March 31, ~~2024~~2025			June 30, 2024
Quoted market price on valuation date	$	0.01		$	0.~~411~~75		$	0.40
Contractual conversion rate	$	0.0054 - $0.0081		$	0.26 – 0.3332		$	0.338 - $0.556
Range of effective contractual conversion rates		-						-
Contractual term to maturity	1.00 Year			0.25 Years			0.25 Years
Market volatility:
Volatility	138.28%-238.13	~~138.28%-238.13~~	%	138.28%-238.13	~~138.28%-238.13~~	%	138.28%-238.13	~~138.28%-238.13~~	%
Contractual interest rate	5%-12	~~5%-12~~	%	5%-12	~~5%-12~~	%	5%-12		%

The following table reflects the issuances of compound embedded derivatives and changes in fair value inputs and assumptions related to the compound embedded derivatives during the ~~six~~nine months ended ~~December~~March 31, ~~2024~~2025 and the year ended June 30, 2024.

	December 31, 2024		June 30, 2024
	March 31, 2025		June 30, 2024
Beginning balance	$	193,557	$	201,607
Issuances:
Convertible Note Financing		-		-
Removals		-		-
Changes in fair value inputs and assumptions reflected		78,~~735~~993		(8,050	)
Conversions		-		-
Ending balance	$	~~201~~202,~~292~~550	$	193,557

The fair value of the compound embedded derivative is significantly influenced by the Company’s trading market price, the price volatility in trading and the interest components of the Monte Carlo Simulation technique.

NOTE 11. STOCKHOLDERS’ DEFICIT

On or about April 26, 2022, the Company entered into an Agreement for Share Exchange (the “Share Exchange Agreement”) to obtain 10,500,000 shares of common stock of Vitality RX, Inc., a Delaware corporation (“Vitality”), representing 100% ownership of Vitality, from Vitality’s five shareholders identified in the Share Exchange Agreement (the “Vitality Shareholders”), in consideration of the issuance by the Company to the Vitality Shareholders of 5,500,000 shares of Innovative common stock, and 50,000 shares of Series A Convertible Preferred Stock (which preferred stock is convertible into 5,000,000 shares of common stock) (such shares of common stock and preferred stock collectively the “Shares”). On or about April 28, 2022, the transaction closed, Innovative received the stock of Vitality from the Vitality Shareholders, and issued the Shares to the Vitality Shareholders. The Company determined that Vitality did not meet the definition of a business under Accounting Standards Codification (“ASC”) 805 Business Combinations, as such, the issuance of shares was treated as stock-based compensation expense.

Table of Contents

Common Stock

On December 20, 2024, the Company filed a Regulation A Securities Offering (the “Offering”) in accordance with the Securities Act of 1933, consisting of equity securities, with a price range of $0.05 to $0.20 per share, for the purpose of raising capital of up to $3,500,000. The Offering was qualified on ~~December~~March 31, ~~2024~~2025.

On December 17, 2024, the Company issued 6,500,000 shares of common stock, par value $0.000001 per share, to Red Halo, LLC, the limited liability company of Company CEO Michael Friedman, in satisfaction of accrued compensation of $325,000 owed to Mr. Friedman and his entity by the Company.

On December 20, 2024 the Company issued 18,000,000 shares of common shares, par value, $0.000001 per share, to several consultants for consulting services and their expertise in healthcare, wound care, technology, franchising, and media.

On December 20, 2024 the Company issued 100,000 shares of common shares, par value, $0.000001 per share, to its new Board of Director Member, Harold Kestenbaum, Esq.

On or about September 11, 2024, the Company issued 2,000,000 common shares, par value, $0.000001 per share, to shareholders of Shear Kershman Labs for the Exclusive License Agreement entered into with the Company.

On or about September 11, 2024, the Company issued 2,036,666 common shares, par value, $0.000001 per share, to several consultants for consulting services and their expertise in technology, financial services and media.

On or about April 12, 2024, the Company issued 1,134,242 common shares, par value, $0.000001 per share, to several consultants for consulting services and their expertise in technology, financial services and media.

On March 7, 2024, the Company issued 1,590,728 restricted common shares, par value, $0.000001 per share, to 6 Board of Advisor Members and 7 consultants to the Company.

On August 21, 2023 the Company issued a Note (Note 7, Ref #7) which included 100,000 warrants to purchase common stock at a strike price of $0.10 per share, par value, $0.000001 per share. The warrants have an expiration date of August 21, 2028.

Conversion of Notes Payable to Common Shares

On April 4, 2024, one Noteholders converted two notes for a total of $11,350 of convertible promissory notes into 50,075 common shares of the Company,

Series A Convertible Preferred Stock

As of June 30, 2024, the Company had 500,000,000 authorized shares of Series A Convertible Preferred Stock, par value, $0.000001 per share. Each share of Series A Convertible Preferred Stock is convertible into 100 shares of the Company’s common stock.

Series A Preferred Stock – Certificate of Designations

The Preferred Shares each have Certificate of Designations, which designate as follows:

Number

500,000,000 shares of the Parent Company’s Preferred Stock are designated as shares of Series A Convertible Preferred Stock, par value $0.000001 per share.

Table of Contents

Dividends

Any dividends (other than dividends on common stock payable solely in common stock or dividends on the Series A Convertible Preferred Stock payable solely in Series A Convertible Preferred Stock or dividends on the Series B Preferred Convertible Stock payable solely in Series B Convertible Preferred Stock) declared or paid in any fiscal year will be declared or paid among the holders of the Series A Convertible Preferred Stock, Series B Convertible Preferred Stock and common stock then outstanding in proportion to the greatest whole number of shares of common stock which would be held by each such holder if all shares of Series A Preferred Stock and Series B Convertible Preferred Stock were converted into shares of common stock pursuant to the terms of the Certificate of Designations. The Parent Company’s Board of Directors is under no obligation to declare dividends on the Series A Convertible Preferred Stock or Series B Convertible Preferred Stock.

Conversion

Each share of Preferred Stock is convertible into 100 shares of the Parent Company’s common stock (the “Conversion Rate”).

Liquidation

In the event of any liquidation, dissolution or winding up of the Parent Company, the assets of the Parent Company legally available for distribution by the Parent Company would be distributed with equal priority and pro rata among the holders of the Preferred Stock and common stock in proportion to the number of shares of common stock held by them, with the shares of Preferred Stock being treated for this purpose as if they had been converted to shares of common stock at the then applicable Conversion Rate.

Voting

On any matter presented to the stockholders of the Parent Company for their action or consideration at any meeting of stockholders of the Parent Company (or by written consent of stockholders in lieu of meeting), each holder of outstanding shares of Preferred Stock would be entitled to cast the number of votes equal to the number of whole shares of common stock into which the shares of Preferred Stock held by such holder are convertible as of the record date for determining stockholders entitled to vote on such matter. Except as provided by law or by the other provisions of the Parent Company’s Certificate of Incorporation, holders of Preferred Stock vote together with the holders of common stock as a single class.

NOTE 12. PROVISION FOR CORPORATE INCOME TAXES

The Company provides for income taxes by the use of an asset and liability approach in accounting for income taxes. Deferred tax assets and liabilities are recorded based on the differences between the financial statement and tax bases of assets and liabilities and the tax rates in effect when these differences are expected to reverse. This also requires the reduction of deferred tax assets by a valuation allowance if, based on the weight of available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized.

The valuation allowance at ~~December~~March 31, ~~2024~~2025 was $11,~~682~~709,~~668~~720 and as of June 30, 2024 was $11,164,600. The net change in allowance during the quarters ended ~~December~~March 31, ~~2024~~2025 was $~~518~~544,~~068~~120 and as of ~~December~~March 31, ~~2023~~2024 was $74264,~~174~~252.

As of ~~December~~March 31, ~~2024~~2025, the Company has federal net operating loss carry forwards of approximately $4445,~~933~~037,~~340~~383 available to offset future taxable income through 2040. The Company may be able to utilize its NOLs to reduce future federal and state income tax liabilities. However, these NOLs are subject to various limitations under Internal Revenue Code (“IRC”) Section 382. IRC Section 382 limits the use of NOLs to the extent there has been an ownership change of more than 50 percentage points. In addition, the NOL carry-forwards are subject to examination by the taxing authority and could be adjusted or disallowed due to such exams. Although the Company has not undergone an IRC Section 382 analysis, it is possible that the utilization of the NOLs could be substantially limited. The Company has no tax provision for the ~~six~~three and nine months ended ~~December~~March 31, ~~2024~~2025 and ~~2023~~2024 due to losses and full valuation allowances against net deferred tax assets.

27As ~~Table~~ of March ~~Contents~~31, 2025 and 2024, the difference between the tax provision at the statutory federal income tax rate and the tax provision attributable to loss before income taxes is as follows (in percentages):

As of June 30, 2024 and 2023, the difference between the tax provision at the statutory federal income tax rate and the tax provision attributable to loss before income taxes is as follows (in percentages):

Statutory federal income tax rate	(21	)%
State taxes – net of federal benefits	(5	)%
Valuation allowance	26	%
Income tax rate – net	0	%

Table of Contents

FASB Interpretation No. 48 (Fin 48) - Accounting for Uncertain Tax Positions

The Company files income tax returns in the U.S. federal jurisdiction and various state, and local jurisdictions. The Company is no longer subject to U.S. federal income tax examination by tax authorities, with limited exception, for the quarters prior to ~~December~~March 31, 2014. With respect to state and local jurisdictions, with limited exception, the Company is no longer subject to income tax audits prior to ~~December~~March 31, 2014. In the normal course of business, the Company is subject to examination by various taxing authorities. Although the outcome of tax audits is always uncertain, the Company believes that adequate amounts of tax, interest and penalties have been provided for any adjustments that may result from these open tax years.

Based on management’s review of the Company’s tax position, the Company had no significant unrecognized corporate tax liabilities as of ~~December~~March 31, ~~2024~~2025 and June 30, 2024 payable to the Internal Revenue Service due to the net operating loss carry-forward, however, the Company had yet to file its 2005 through 2009 and 2012 through 2021 Federal, New Jersey nor New York Corporate Income Tax Returns.

NOTE 13. UNPAID PAYROLL TAXES

As of ~~December~~March 31, ~~2024~~2025 and June 30, 2024, the Company owed the Internal Revenue Service and New York State payroll related taxes in the amounts of $60,402 and $17,401, respectively, subject to further interest and penalties. The total amount due to both taxing authorities including penalties and interest as of ~~December~~March 31, ~~2024~~2025 and June 30, 2024 was approximately $77,803 subject to further penalties and interest. This is included in accounts payable and accrued expenses on the Company’s consolidated balance sheets.

IRS Tax Lien

The Internal Revenue Service has placed a federal tax lien on all of the assets of the Company.

NOTE 14. COMMITMENTS AND CONTINGENCIES

Rent

As of ~~December~~March 31, ~~2024~~2025, the Company maintains its corporate address in at 2310 York Street, Suite 200, Blue Island, IL, 60406. This space is provided by the Company’s Chairman, Charles Everhardt, a related party, on a rent free basis at the present time. The Company does not currently have a lease for this space but expects to enter into a month-to-month office lease for this space.

SarahCare leases two properties for its corporate office and its one corporate owned centers. SarahCare’s lease for its first corporate-owned SarahCare location is for approximately 5,300 square feet located at 6199 Frank Ave. NW, North Canton, Ohio, 44720. The lease began in 2018 and ends in 2026.

SarahCare’s lease for its second corporate-owned SarahCare location is for approximately 6,000 square feet located at SarahCare of Stow, 4472 Darrow Road, Stow, Ohio, 44224. The lease began in 2018 and ends in 2026. SarahCare closed this location in April 2024. The Company is currently negotiating with the landlord to find a new tenant and to repay the remaining amounts due on this lease.

SarahCare

The Company is currently in default under its payment obligations in connection with the acquisition of SarahCare. The Company has $1.5 Million Dollars on its balance sheet for the payment obligation due SarahCare, for the ~~years~~quarter ending ~~June~~March 3031, ~~2024~~2025 and the year ending June 30, ~~2023~~2024. The Company is ~~involved~~ in anegotiations ~~lawsuit~~to ~~with~~sell ~~the original shareholders of~~ SarahCare~~, who are seeking $1,841,537 in damages, plus interests, costs and attorney fees; this amount includes the original $1~~.~~5 Million. The Company intends to vigorously defend itself in this matter, and believes that the likelihood of a negative outcome is considered to be remote.~~

28The ~~Table~~Company is currently in default under its payment obligations in connection with the acquisition of ~~Contents~~SarahCare. The Company has $1.5 Million Dollars on its balance sheet for the payment obligation due SarahCare, for the years ending June 30, 2024 and June 30, 2023. The Company is in negotiations to sell SarahCare.

Litigation

On or about October 2, 2024, SarahCare was notified that a complaint had been filed in the Court of Common Pleas, Summit County, Ohio, by the landlord of the Stow Professional Center, alleging breach of contract, unjust enrichment, and promissory estoppel for SarahCare vacating the Stowe property prior to the end of the lease. The plaintiff is asking for $75,000 plus legal expenses, costs and fees. The Company intends to vigorously defend itself in this matter.

On28 orTable ~~about October 2, 2024, Sarah Adult Day Services, Inc. was named as a defendant in a complaint filed in the Summit County Court~~ of Common Please, Summit County Courthouse in Akron, OH (case no.: CV-2024-10-4369), but Premier Wadsworth Property, LLC (the “Plaintiff”), who is the owner and landlord for the Stow Professional Center, where SarahCare had a corporate center, which it closed around April 2024, approximately 1 year prior to the term of the lease. The Plaintiff alleges that it is owed damages totaling at least $102,407, including all rent, utilities, and attorney’s fees. The Company intends to vigorously defend itself in this matter.Contents

On or about ~~April~~October 172, 2024, ~~the~~Sarah ~~Company~~Adult Day Services, Inc. was ~~notified~~named ~~that~~as a ~~complaint~~defendant ~~had~~in ~~been~~a complaint filed ~~against it~~ in the ~~United~~Summit ~~States~~County ~~District~~ Court ~~for~~of ~~the~~Common ~~Northern~~Please, ~~District~~Summit ofCounty ~~Ohio,~~Courthouse ~~Eastern~~in ~~Division~~Akron, OH (case no. 5:24 CV-cv2024-~~00687~~10-4369), bybut ~~Merle~~Premier ~~Griff~~Wadsworth Property, ~~Adam~~LLC ~~Griff and Brian Froelich~~ (the “~~Plaintiffs~~Plaintiff”), who ~~are~~is the ~~original~~owner ~~shareholders~~and oflandlord ~~SarahCare,~~for ~~which~~the isStow ~~wholly~~Professional ~~owned~~Center, bywhere ~~the~~SarahCare ~~Company,~~had ~~alleging~~a ~~breach~~corporate ofcenter, ~~breach~~which ofit ~~contract~~closed ~~and~~around ~~related~~April ~~causes~~2024, ofapproximately ~~action~~1 inyear ~~connection~~prior ~~with~~to ~~unpaid~~the ~~royalties~~term ~~pursuant~~of to the ~~Company’s~~lease. The ~~original~~Plaintiff ~~purchase~~alleges ~~agreement~~that init ~~connection~~is ~~with~~owed ~~SarahCare,~~damages ~~and~~totaling ~~seeking~~at least $1102,~~841~~407,~~537~~ inincluding ~~damages~~all rent, ~~plus interests~~utilities, ~~costs~~ and attorney’s fees. The Company intends to vigorously defend itself in this matter. The Company has been paying down this liability and negotiating a settlement with the Plaintiff.

On or about April 17, 2024, the Company was notified that a complaint had been filed against it in the United States District Court for the Northern District of Ohio, Eastern Division (case no. 5:24-cv-00687), by Merle Griff, Adam Griff and Brian Froelich (the “Plaintiffs”), who are the original shareholders of SarahCare, which is wholly owned by the Company, alleging breach of breach of contract and related causes of action in connection with unpaid royalties pursuant to the Company’s original purchase agreement in connection with SarahCare, and seeking $1,841,537 in damages, plus interests, costs and attorney fees. The matter was resolved and dismissed by the courts for improper jurisdiction. The Plaintiffs have not filed another complaint since the dismissal.

Additionally, we currently have thirteen (13) convertible promissory notes that are in default, and we may be subject to legal proceedings or lawsuits from any number of those convertible noteholders, including the below.

On April 7, 2013, three note holders (Brook Hazelton, Benjamin M. Manalaysay, Jr., and Diego McDonald, the “Plaintiffs”), whom together invested a total principal amount of $45,000 in the form of Convertible Promissory Notes (the ”“Notes”) to the Company, together filed a “Notice of Commencement of Action Subject to Mandatory Electronic Filing” in the Supreme Count of the State of New York, County of New York. The Plaintiffs alleged that the Company breached their contracts with the Plaintiffs and included causes of action for unjust enrichment and related claims, seeking repayment of each of their respective convertible promissory notes plus interest. On or about February 24, 2014, the three Plaintiffs received judgment against the Company from the court in the amounts of $33,686, $8,546 and $33,696 respectively.

NOTE 15. RELATED PARTY TRANSACTIONS

During the periods ended ~~December~~March 31, ~~2024~~2025 and ~~2023~~2024, related party transactions were as follows:

On February 1, 2025, the Company, entered into a lease (the “Lease Agreement” or the “Lease”) for Suite 690, consisting of 9,500 square feet within the premises located at 11680 Great Oaks Way, Alpharetta, GA. The Company’s landlord for this location is Georgia Commercial Holdings, LLC, a limited liability company which our Chairman, Charles Everhardt is a Managing Member. The Lease begins March 1, 2025, will be for a term of 10 years at an initial rate of $25.50 psf with an annual rental increase of 2.5%.

Simultaneous with the execution of the Lease, the Company entered into a sublease (the “sub-Lease”) of the premises to Lockwood Alpharetta Manager Inc, (the “sub-Tenant”), an entity which will use the premises for its medical, lab and administrative uses, and which sub-Tenant will be responsible for all fees, requirements and potential liabilities under the lease. Charles Everahrdt, the ~~Compan~~Company’s Chairman is a Managing Member of the sub-Tenant. The sublease will be for a term of 10 years at an initial rate of $30 psf with an annual rental increase of 2.5%. The Company has no liability in this transaction, as sub-Tenant shall be solely responsible for all expenses, rents, payments, liabilities, etc.

Table of Contents

As of June 30, 2024, a company founded and partially owned by the Company’s Chairman, Charles Everhardt, has been assigned the $3,750,000 in payables to a Company owned by Charle’s Everhardt for the Vitality Card, this amount included $750,000 which was included in accounts payable and accrued expenses as of ~~June~~March 3031, ~~2023~~2025.

The above amounts and terms are not necessarily what third parties would agree to.

NOTE 16. SUBSEQUENT EVENTS

The Company has evaluated subsequent events for recognition and disclosure through ~~February~~May __20, 2025 the date the financial statements were available to be issued, and determined that there were no such events requiring adjustment to, or disclosure in, the accompanying consolidated financial statements except as described below.

On ~~February~~or 5about April 25, 2025, Innovative MedTech, Inc. (“Innovative” or the “Company”) ~~defaulted~~entered oninto an Asset Purchase Agreement (the ~~Promissory~~“Asset ~~Note~~Acquisition Agreement”), ~~entered~~pursuant ~~into~~to onwhich ~~July~~a 30newly formed subsidiary of the Company (the “New Subsidiary”) would purchase (the “Purchase”) assets of Grand Concierge LLC, ~~2024~~d/b/a Ticketbash, a New York limited liability company (“Ticketbash”) associated with retail and wholesale event ticket pricing, and the development of software and artificial intelligence related to the ticket business (the “Assets”), in consideration of (i) the ~~amount~~issuance by the Company to Ticketbash’s owners of 20,000,000 shares of common stock and 1,151,500 shares of Series A Convertible Preferred Stock (which preferred stock is convertible into 115,150,000 shares of common stock) (such shares of common stock and preferred stock collectively the “Shares”), and additional shares as necessary to ensure that the shares issued constitute 60% of the total number of fully diluted shares of the Company, (ii) the future payment of two million dollars ($402,~~250~~000,000) atto anTicketbash ~~interest~~based ~~rate~~on net revenue and income milestones to be determined by the parties in the future, and (iii) the future payment of 14percentage royalties to Ticketbash based on aggregate revenues generated by the New Subsidiary as follows: 2% of revenue up to $15,000,000, 4% of revenue from $15,000,000-$25,000,000, and a5% ~~maturity~~of ~~date~~revenue in excess of ~~May~~$25,000,000. 30In connection with the Purchase, ~~2025~~Ticketbash also received the right to appoint two members of the Board of Directors of the Company. ~~The~~On ~~Company~~or ~~and~~about May 15, 2025, Ticketbash advised that because of a lien on its assets by a lender, the ~~Lender~~close ~~are~~of ~~working~~the ~~together~~Purchase would need to be delayed, and the ~~Company~~parties ~~has~~are ~~made~~currently ~~partial~~negotiating ~~payments~~an ~~while~~amendment ~~working~~to the Asset Acquisition Agreement to ~~cure~~provide for the ~~default~~payoff of the lender at closing. The Asset Acquisition Agreement is being accounted for as a reverse acquisition in accordance with ASC §805.

On February 5, 2025, the Company defaulted on the Promissory Note Agreement entered into on July 30, 2024 in the amount of $51,750, at an interest rate of 14% and a maturity date of May 30, 2025. The Company and the Lender are working together and the Company has made partial payments while working to cure the default.

On February 1, 2025 the Company entered into Lease and sub-Lease Agreements, as described herein Note 15. Related Party Transactions.

On January 30, 2025, the Company entered into a non-binding Letter of Intent (“LOI”) for a proposed strategic alliance with Miami Sun. Miami Sun has developed an all-natural lip balm, which Miami Sun is currently selling to consumers. The LOI contemplates the Company purchasing an equity stake in Miami Sun and a royalty interest in Miami Sun’s future lip balm sales using a combination of Company cash and equity. The parties are currently in discussions regarding the transactions.

On January 28, 2025, the Company entered into a non-binding Summary of Terms with Spinal Concepts LLC (“SC”), to purchase certain neurosurgical and spine business assets of SC. The Summary of Terms contemplates the Company acquiring an equity stake in SC, issuing shares of Company common stock to SC, and securing financing for the neurosurgical and spine business. The parties are currently in discussions and believe that Craft Capital Management LLC, a registered broker, will be able to secure bridge financing and follow-on financing in the future.

On January 5, 2025, the Company signed an Asset Purchase Agreement (“APA”) with AI Health Technologies, Inc. to acquire its newly developed CyberHealthAI (“CHAI”) system. This cutting-edge technology is designed to create an all-in-one universe for healthcare providers that includes refresher training, real time measurements, and video documentation of the entire procedure. CHAI was originally developed for wound care procedures but has been found to bring added value to many other health care services as well. Sales and licensing agreements in connection with the CHAI system are expected to begin in the 2nd quarter of 2025 (assuming the acquisition closes). By its terms, the APA is not considered binding until IMTH has completed its due diligence, and there is no guarantee that the acquisition will close.

Table of Contents

Item 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITIONS AND RESULTS OF OPERATIONS

Forward Looking Statements

Some of the information in this section contains forward-looking statements that involve substantial risks and uncertainties. You can identify these statements by forward-looking words such as “may,” “will,” “expect,” “anticipate,” “believe,” “estimate” and “continue,” or similar words.

We believe it is important to communicate our expectations. However, there may be events in the future that we are not able to accurately predict or over which we have no control. Our actual results and the timing of certain events could differ materially from those anticipated in these forward-looking statements as a result of certain factors, including those set forth elsewhere in this Quarterly Report on Form 10-Q.

Unless stated otherwise, the words “we,” “us,” “our,” “the Company” or “Innovative MedTech” in this Quarterly Report on Form 10-Q collectively refers to Innovative MedTech, Inc., a Delaware corporation (the “Parent Company”), and subsidiaries.

Overview

Innovative MedTech, Inc. (the “Company”), a Delaware corporation, is a provider of health and wellness services. On March 25, 2021, the Company acquired two companies, Sarah Adult Day Services, Inc., and Sarah Day Care Centers, Inc. (collectively “SarahCare”), an adult day care center franchisor and provider. With 25 centers (1 corporate and 24 franchise locations) located in 13 states, SarahCare offers seniors daytime care and activities focusing on meeting their physical and medical needs on a daily basis, and ranging from nursing care to salon services and providing meals, to offering engaging and enriching activities to allow them to continue to lead active and engaged lives.

The Company is a provider of health and wellness services and has two divisions: technology and devices and Adult Day Services. The Company’s technology and devices division has signed a distribution agreement with 2 products: a high detection vein visualization device and an Oral Thrush product, and the Company’s wholly owned subsidiary SarahCare, an adult day care center franchisor with 1 corporate owned center and 24 franchise locations across the United States. SarahCare offers seniors daytime care and activities ranging from exercise and medical needs daily to nursing care and salon services.

On March 25, 2021, the Company acquired two companies, Sarah Adult Day Services, Inc., and Sarah Day Care Centers, Inc. (collectively “SarahCare”), an adult day care center franchisor and provider. On March 25, 2021, the Company acquired two companies, Sarah Adult Day Services, Inc., and Sarah Day Care Centers, Inc. (collectively “SarahCare”), an adult day care center franchisor and provider. At that time, SarahCare had 25 centers (2 corporate and 23 franchise locations) located in 13 states, SarahCare offers seniors daytime care and activities focusing on meeting their physical and medical needs on a daily basis, and ranging from nursing care to salon services and providing meals, to offering engaging and enriching activities to allow them to continue to lead active and engaged lives. The Company is currently planning to sell its wholly-owned subsidiaries Sarah Adult Day Services, Inc., and Sarah Day Care Centers, Inc. Accordingly, the Company categorized the operations of Sarah Adult Day Services, Inc., and Sarah Day Care Centers, Inc. as discontinued operations in our financial statements for the three and ~~six~~nine months ended ~~December~~March 31, ~~2024~~2025 and ~~2023~~2024.

On or about April 16, 2024, the Company entered into a distribution agreement (the “Agreement”) with Near Infrared Imaging, Inc. (“NII”) for Vein-Eye Carry, a patent-pending vein illumination technology which employs advanced optics and real-time imaging to precisely identify veins, reducing the need for multiple attempts and enhancing procedural accuracy. The Agreement gives the Company the non-exclusive right to distribute NII’s product(s) with no limitations on the territory. NII’s Vein-Eye Carry is a Class 1, 510-k exempt medical device, is TAA and FAR compliant, and is designed, engineered and manufactured in the U.S. The Vein-Eye Carry is lightweight and portable and can be successfully carried into a home, up flights of stairs, carried into a clinic nursing home, placed in an ambulance or another emergency medical vehicle. On December 15, 2024, the Company was notified by NII that NII would be exercising the thirty (30) notice for termination of the Agreement between the companies.

Table of Contents

On or about April 16, 2024, the Company entered into a distribution agreement (the "Agreement") with Near Infrared Imaging, Inc. ("NII") for Vein-Eye Carry, a patent-pending vein illumination technology which employs advanced optics and real-time imaging to precisely identify veins, reducing the need for multiple attempts and enhancing procedural accuracy. The Agreement gives the Company the non-exclusive right to distribute NII's product(s) with no limitations on the territory. NII's Vein-Eye Carry is a Class 1, 510-k exempt medical device, is TAA and FAR compliant, and is designed, engineered and manufactured in the U.S. The Vein-Eye Carry is lightweight and portable and can be successfully carried into a home, up flights of stairs, carried into a clinic nursing home, placed in an ambulance or another emergency medical vehicle. On December 15, 2024, the Company was notified by NII that NII would be exercising the thirty (30) notice for termination of the Agreement between the companies.

On or about May 17, 2024, the Company entered into an Exclusive License Agreement (the “Exclusive License Agreement”) with Shear Kershman Labs, a Missouri corporation (“SKL”). SKL has developed Oral Thrush, a mouth wash that treats oral thrush, a condition in which a fungus, Candida albicans, accumulates on the lining of the mouth and sometimes overgrows and causes symptoms, such as creamy white lesions, usually on the tongue or inner cheeks. Under the Exclusive License Agreement, SKL is to form a subsidiary to distribute Oral Thrush, the Company is to become an 80% owner of the subsidiary, and the Company was required to issue 2,000,000 shares of the Company’s Common Stock to SKL, which shares have been issued.

On or about December 20, 2024, Texas A&M University College of Dentistry and Shear-Kershman Laboratories (“SKL”) have signed a Memorandum of Understanding (MOU) to collaborate on transformative healthcare initiatives in oral care, including performing a bioequivalency study for Oral Thrush.

IMTH has recently signed consulting agreements with two highly experienced wound care specialists to manage the Company’s expansion into the burgeoning advanced wound care market. IMTH expects to utilize the biological amnionic membrane allograft which has proven to be a dramatic leap forward in wound care with a very high success rate for closing and healing infected wounds, far beyond anything that has previously been achieved. IMTH’s new consultants have contracts with two of the largest distributors for biological amnion membrane allografts. Their primary objectives are to pursue potential wound care acquisitions and partnerships for IMTH and to make IMTH an active sales representative to the largest consumers of wound care services, including wound care centers, nursing homes, assisted living centers, podiatrists, etc. IMTH is committed to becoming a major player in advanced wound care treatment.

On January 5, 2025, IMTH signed an Asset Purchase Agreement (“APA”) with AI Health Technologies, Inc. to acquire its newly developed CyberHealthAI system. This cutting-edge technology is designed to create an all-in-one universe for healthcare providers that includes refresher training, real time measurements, and video documentation of the entire procedure. CyberHealthAI was originally developed for wound care procedures but has been found to bring added value to many other health care services as well. Sales and licensing agreements in connection with the CyberHealthAI system are expected to begin in the 2nd quarter of 2025 (assuming the acquisition closes). By its terms, the APA is not considered binding until IMTH has completed its due diligence, and there is no guarantee that the acquisition will close. CyberHealthAI is focused on fusing the patient healthcare experience with a newly developed Artificial Intelligence / Virtual Reality system that creates an innovative environment for healthcare providers to deliver top level treatments / procedures to their patients. The system is designed to allow providers to access everything they need right at their fingertips, while exceeding government and commercial insurance guidelines and protocols. The Company has terminated discussions with this company under the APA.

The following Management Discussion and Analysis should be read in conjunction with the financial statements and accompanying notes included in this Form 10-Q.

As of ~~December~~March 31, ~~2024~~2025, the Company had current assets of $1250,~~132,186~~386. The Company has a limited amount of liquid cash and no other liquid assets on hand as As of ~~December~~March 31, ~~2024~~2025, and this is not sufficient to fund operations for the next 12 months. Accordingly, we will be required to raise additional funds to meet our short and long-term planned goals. There can be no assurance that such funds, if available at all, can be obtained on terms reasonable to us. In this regard, we have obtained and will continue to attempt to obtain (short and long term) loans for inventory purchases, new product development, expansion, advertising and marketing. We cannot assure you that we will be successful in obtaining the aforementioned financings (either debt or equity) on terms acceptable to us, or otherwise. These conditions raise substantial doubt about the Company’s ability to continue as a going concern. The accompanying consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.

Our unaudited consolidated financial statements contained in this Quarterly Report on Form 10-Q have been prepared on a going concern basis, which assumes that we will be able to realize our assets and discharge our obligations in the normal course of business.

Table of Contents

Results of Operations for the Three months ended ~~December~~March 31, ~~2024~~2025, and ~~December~~as of March 31, ~~2023~~2024

For the quarter ended ~~December~~March 31, ~~2024~~2025, we recorded gross revenues of $0 versus $0 for the quarter ended ~~December~~as of March 31, ~~2023~~2024, as a result of the Company’s reclassification from discounted operations.

For the quarter ended ~~December~~March 31, ~~2024~~2025, operating expenses ~~increased~~decreased to $156,~~074,176~~659 from $93865,~~834~~194, aan $~~980~~808,~~342 increase~~535 decrease, or ~~1045~~93.45%, over the quarter ended ~~December~~as of March 31, ~~2023~~2024. The ~~increase~~decrease is due to ana ~~increase~~decrease in consulting expenses, stock -based compensation and general and administrative expenses.

For the quarter ended ~~December~~March 31, ~~2024~~2025, other ~~income~~ (expense) income decreased to ($3460,~~864~~851) from $~~36,083~~89 a decrease of 368,472% over the quarter ended ~~December~~as of March 31, ~~2023~~2024. This decrease is primarily due to aan ~~decrease~~increase in amortization of debt discount, ~~expense~~loss on change in fair value of derivatives, and an increase in interest expenses.

For the quarter ended ~~December~~March 31, ~~2024~~2025, we realized a net loss of $1117,~~124,333~~510 as compared to a net loss of $~~188~~865,~~145~~105 for the quarter ended ~~December~~as of March 31, ~~2023~~2024. The ~~increase~~decrease in our net loss of $~~1936~~747,~~188~~595 was primarily due to ana ~~increase~~decrease in consulting, general and administrative expenses and stock -based compensation.

Results of Operations for the ~~Six~~Nine Months Ended ~~December~~March 31, ~~2024~~2025, and ~~December~~as of March 31, ~~2023~~2024

For the ~~six~~nine months ended ~~December~~March 31, ~~2024~~2025, we recorded gross revenues of $0 versus $0 for the ~~six~~nine months ended ~~December~~as of March 31, ~~2023~~2024, as a result of the Company’s reclassification from discounted operations.

For the ~~six~~nine months ended ~~December~~March 31, ~~2024~~2025, operating expenses increased to $12,~~971~~028,~~672~~331 from $~~191~~1,~~231~~056,425, a $1971,~~780,441~~906 increase, or ~~931~~92.00%, over the ~~six~~nine months ended ~~December~~as of March 31, ~~2023~~2024. The increase is due to an increase in consulting expenses, stock -based compensation, legal and professional and general and administrative expenses.

For the ~~six~~nine months ended ~~December~~March 31, ~~2024~~2025, other expense ~~decreased~~increased to $78139,~~677~~528 from $94,~~307~~218, aan ~~decrease~~increase of 1748.09% over the ~~six~~nine months ended ~~December~~as of March 31, ~~2023~~2024. This ~~decrease~~increase is primarily due to a ~~decrease~~loss inon the change in fair value of derivatives and ~~amortization~~an ofincrease ~~debt~~in ~~discount~~interest expense.

For the ~~six~~nine months ended ~~December~~March 31, ~~2024~~2025, we realized a net loss of $2,~~007~~167,~~864~~859 as compared to a net loss of $~~353~~1,~~208~~150,643 for the ~~six~~nine months ended ~~December~~as of March 31, ~~2023~~2024. The increase in our net loss of $1,~~654~~017,~~656~~216 was primarily due to an increase in consulting expenses, stock -based compensation and ~~general~~legal and ~~administrative~~professional expenses.

Results of Discontinued Operations for the Three months ended ~~December~~March 31, ~~2024~~2025, and ~~December~~as of March 31, ~~2023~~2024

For the quarter ended ~~December~~March 31, ~~2024~~2025, we recorded gross revenues from discontinued operations of $~~414~~431,~~696~~017 versus $~~432~~455,~~691~~164 for the quarter ended ~~December~~as of March 31, ~~2023~~2024. The decrease of $1724,~~995~~147 was a result of participant fees decreasing by $3230,~~794~~643 offset by an increase in franchise fees of $146,~~799~~496.

For the quarter ended March 31, 2025, operating expenses from discontinued operations decreased to $392,348 from $491,976, a $99,628 decrease, or 20.25%, over the quarter ended as of March 31, 2024. The decrease is primarily due to a decrease in general and administrative and salaries and wages expenses in the amount of $94,642, offset by an increase in professional and consulting fees in the amount of $4,986.

For the quarter ended March 31, 2025, other income from operations of discontinued operations increased to ($9,910) from ($7,955), an increase of 24.59% over the quarter ended as of March 31, 2024. This increase of $1,955 is primarily due to an increase in interest expense in the amount of ($2,346) and other income of $391.

For the quarter ended March 31, 2025, gain (loss) from operations of discontinued operations increased to $28,759 from ($44,767), an increase of 164.24% over the quarter ended as of March 31, 2024. This increase is primarily due to an increase in operating expenses.

Table of Contents

~~For~~Results ~~the~~of ~~quarter~~Discontinued ~~ended~~Operations ~~December~~for ~~31, 2024, operating expenses decreased to $435,810 from $495,612, a $59,802 decrease, or 12.07%, over~~ the ~~quarter~~Nine ~~ended~~Months ~~December~~Ended March 31, ~~2023. The decrease of $59~~2025,~~802~~ ~~is primarily due to a decrease in general~~ and ~~administrative~~as ~~expenses, consulting expenses and personnel expenses in the amount~~ of ~~$75,275~~March ~~offset by an increase in professional fees in the amount of $15~~31,~~473.~~ 2024

For the ~~quarter~~nine months ended ~~December~~March 31, ~~2024~~2025, ~~other~~we ~~income~~recorded ~~from~~gross ~~operations~~revenues offrom discontinued operations ~~increased~~of to $51,~~821~~274,081 ~~from~~versus $41,~~693~~368,564 anfor ~~increase~~the ofnine ~~24,04%~~months ~~over~~ended ~~the~~as ~~quarter~~of ~~ended~~March ~~December~~ 31, ~~2023~~2024. The ~~This~~decrease ~~increase~~ of $194,~~128~~483 iswas ~~primarily~~a ~~due~~result toof anparticipant ~~increase~~fees indecreasing ~~interest~~by ~~expense in the amount of~~ $2132,~~848~~372 offset by aan ~~decrease~~increase in ~~interest~~franchise ~~income~~fees ~~in the amount~~ of $337,~~977~~889.

For the ~~quarter~~nine months ended ~~December~~March 31, ~~2024~~2025, ~~loss~~operating ~~(gain)~~expenses from ~~operations of~~ discontinued operations decreased to ($151,~~293)~~185,764 from ($581,~~228)~~517,707, a $331,943 decrease, ofor ~~73,74~~21.87%, over the ~~quarter~~nine months ended ~~December~~as of March 31, ~~2023~~2024. ~~This~~The decrease of $331,943 is primarily due to ana decrease in ~~operating~~general and administrative expenses, salaries & wages and consulting expenses in the amount of $346,032 offset by an increase in legal & professional fees in the amount of $11,539.

For the ~~quarter~~nine months ended ~~December~~March 31, ~~2024~~2025, other income ~~(expense)~~ from operations of discontinued operations ~~increased~~decreased to ($517,~~821~~072) from $436,~~693~~706, ana ~~increase~~decrease of 24146.0451% over the quarter ended ~~December~~as of March 31, ~~2023~~2024. This ~~increase~~decrease of $53,778 is primarily due to a decrease in other income of $48,636 offset by an increase in interest expense in the amount of $5,142.

For the ~~quarter~~nine months ended ~~December~~March 31, ~~2024~~2025, ~~loss~~gain (~~gain~~loss) from operations of discontinued operations ~~decreased~~increased to ($1571,~~293)~~245 from ($58112,~~228~~437), aan ~~decrease~~increase of ~~73,74~~163.36% over the ~~quarter~~nine months ended ~~December~~as of March 31, ~~2023~~2024. This ~~decrease~~increase is primarily due to aan ~~decrease~~increase in ~~operating~~discontinued ~~expenses~~operations.

Results of Discontinued Operations for the Six Months Ended December 31, 2024, and December 31, 2023

For the six months ended December 31, 2024, we recorded gross revenues of $843,080 versus $913,399 for the six months ended December 31, 2023. The decrease of $70,319 was a result of participant fees decreasing by $101,713 offset by an increase in franchise fees of $31,394.

For the six months ended December 31, 2024, operating expenses decreased to $793,441 from $1,025,730, a $232,289 decrease, or 22.64%, over the six months ended December 31, 2023. The decrease of $232,289 is primarily due to a decrease in general and administrative expenses, consulting expenses and personnel expenses in the amount of $239,292 offset by an increase in professional fees in the amount of $7,003.

For the six months ended December 31, 2024, other income from operations of discontinued operations decreased to $44,661 from ($7,154), a decrease of 116% over the quarter ended December 31, 2023. This decrease of $51,815 is primarily due to a decrease in interest expense in the amount of $2,795 offset by an increase in interest income in the amount of $49,028.

For the six months ended December 31, 2024, gain (loss) from operations of discontinued operations increased to $42,485 from ($67,670), an increase of 162.79% over the six months ended December 31, 2023. This increase is primarily due to an increase in discontinued operations.

For the six months ended December 31, 2024, other income (expense) expense decreased to ($7,154) from $44,661, a decrease of 116% over the six months ended December 31, 2023. This decrease is primarily due to a decrease in other income.

For the six months ended December 31, 2024, we realized a net gain from operations of discontinued operations of $42,485 as compared to a net loss of ($67,670) for the six months ended December 31, 2024. The decrease in our net loss of $110,155 was primarily due to a decrease in operating expenses.

Liquidity and Capital Resources

Based upon our current financial condition, we do not have sufficient cash to operate our business at the current level for the next twelve months. We intend to fund operations through debt and/or equity financing arrangements, which may be insufficient to fund expenditures or other cash requirements. We plan to seek additional financing in a private equity offering to secure funding for operations. There can be no assurance that we will be successful in raising additional funding. If we are not able to secure additional funding, the implementation of our business plan will be impaired. There can be no assurance that such additional financing will be available to us on acceptable terms or at all. These conditions raise substantial doubt about the Company’s ability to continue as a going concern. The accompanying consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.

Off Balance Sheet Arrangements

We currently have no off-balance sheet arrangements that have or are reasonably likely to have a current or future material effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources.

34 Table of Contents

Critical Accounting Policies

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires us to make a number of estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements. Such estimates and assumptions affect the reported amounts of revenues and expenses during the reporting period. We base our estimates on historical experiences and on various other assumptions that we believe to be reasonable under the circumstances. Actual results may differ materially from these estimates under different assumptions and conditions. We continue to monitor significant estimates made during the preparation of our financial statements. On an ongoing basis, we evaluate estimates and assumptions based upon historical experience and various other factors and circumstances. We believe our estimates and assumptions are reasonable in the circumstances; however, actual results may differ from these estimates under different future conditions.

Derivative financial instruments

Table of Contents

Going Concern

35 Table of Contents

Inflation

We do not believe that inflation had a significant impact on our results of operations for the periods presented.

Item 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

We are a smaller reporting company, as defined in Rule 12b-2 of the Securities Exchange Act of 1934 and are not required to provide the information under this item.

Item 4. CONTROLS AND PROCEDURES

Evaluation of Disclosure Controls and Procedures

In connection with the preparation of this Quarterly Report on Form 10-Q, an evaluation was carried out by the Company’s management, with the participation of the principal executive officer and the principal financial officer, of the effectiveness of the Company’s disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934 (“Exchange Act”)) as of ~~December~~March 31, ~~2024~~2025. Disclosure controls and procedures are designed to ensure that information required to be disclosed in reports filed or submitted under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in the Commission’s rules and forms, and that such information is accumulated and communicated to management, including the chief executive officer and the chief financial officer, to allow timely decisions regarding required disclosures.

Table of Contents

Based on that evaluation, the Company’s principal executive officer and principal financial officer concluded, as of the end of the period covered by this report, that the Company’s disclosure controls and procedures were not effective in recording, processing, summarizing, and reporting information required to be disclosed, within the time periods specified in the Commission’s rules and forms, and that such information was not accumulated and communicated to management, including the principal executive officer and the principal financial officer, to allow timely decisions regarding required disclosures.

Management’s Report on Internal Control over Financial Reporting

The management of the Company is responsible for establishing and maintaining adequate internal control over financial reporting. The Company’s internal control over financial reporting is a process, under the supervision of the principal executive officer and the principal financial officer, designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of the Company’s financial statements for external purposes in accordance with United States generally accepted accounting principles (GAAP). Internal control over financial reporting includes those policies and procedures that:

	●	Pertain to the maintenance of records that in reasonable detail accurately and fairly reflect the transactions and dispositions of the Company’s assets;
	●	Provide reasonable assurance that transactions are recorded as necessary to permit preparation of the financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures are being made only in accordance with authorizations of management and the board of directors; and
	●	Provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the Company’s assets that could have a material effect on the financial statements.

36 Table of Contents

Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions or that the degree of compliance with the policies or procedures may deteriorate.

The Company’s management conducted an assessment of the effectiveness of our internal control over financial reporting Asas of ~~December~~March 31, ~~2024~~2025, based on criteria established in Internal Control – Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission, which assessment identified material weaknesses in internal control over financial reporting. A material weakness is a control deficiency, or a combination of deficiencies in internal control over financial reporting that creates a reasonable possibility that a material misstatement in annual or interim financial statements will not be prevented or detected on a timely basis. Since the assessment of the effectiveness of our internal control over financial reporting did identify a material weakness, management considers its internal control over financial reporting to be ineffective.

Management has concluded that our internal control over financial reporting had the following deficiency:

●

We were unable to maintain any segregation of duties within our business operations due to our reliance on a single individual fulfilling the role of sole officer. This control deficiency did result in adjustments to our 2024 and 2023 interim and annual financial statements. Accordingly, we have determined that this control deficiency constitutes a material weakness.

To the extent reasonably possible, given our limited resources, our goal is, upon sufficient operating cash flow and/or capital, to separate the responsibilities of principal executive officer and principal financial officer, intending to rely on two or more individuals. We will also seek to expand our current board of directors to include additional individuals willing to perform directorial functions. Since the recited remedial actions will require that we hire or engage additional personnel, this material weakness may not be overcome in the near term due to our limited financial resources. Until such remedial actions can be realized, we will continue to rely on the advice of outside professionals and consultants.

This Quarterly Report on Form 10-Q does not include an attestation report of our independent registered public accounting firm regarding internal control over financial reporting. We were not required to have, nor have we, engaged our independent registered public accounting firm to perform an audit of internal control over financial reporting pursuant to the rules of the Commission that permit us to provide only management’s report in this Quarterly Report on Form 10-Q.

Changes in Internal Controls over Financial Reporting

During the quarter ended ~~December~~March 31, ~~2024~~2025, there has been no change in internal control over financial reporting that has materially affected, or is reasonably likely to materially affect our internal control over financial reporting.

3736 Table of Contents

PART II - OTHER INFORMATION

Item 1. Legal Proceedings.

From time to time, we may be involved in litigation relating to claims arising out of our operations in the normal course of business. Other than disclosed herein, there were no pending or threatened lawsuits that could reasonably be expected to have a material effect on the results of our operations.

On or about October 2, 2024, Sarah Adult Day Services, Inc. was named as a defendant in a complaint filed in the Summit County Court of Common Please, Summit County Courthouse in Akron, OH (case no.: CV-2024-10-4369), by Premier Wadsworth Property, LLC (the “Plaintiff”), who is the owner and landlord for the Stow Professional Center, where SarahCare had a corporate center, which it closed around April 2024, approximately 1 year prior to the term of the lease. The Plaintiff alleges that it is owed damages totaling at least $102,407, including all rent, utilities, and attorney’s fees. The Company intends to vigorously defend itself in this matter and is currently in settlement negotiations, and making payments towards a settlement, while in the initial motion stages of the litigation.

On or about April 17, 2024, the Company was notified that a complaint had been filed against it in the United States District Court for the Northern District of Ohio, Eastern Division (case no. 5:24-cv-00687), by Merle Griff, Adam Griff and Brian Froelich (the “Plaintiffs”), who are the original shareholders of SarahCare, which is wholly owned by the Company, alleging breach of breach of contract and related causes of action in connection with unpaid royalties pursuant to the Company’s original purchase agreement in connection with SarahCare, and seeking $1,841,537 in damages, plus interests, costs and attorney fees. The ~~Company~~matter ~~intends~~was toresolved ~~vigorously~~and ~~defend~~dismissed ~~itself~~by inthe ~~this~~courts ~~matter~~for ~~and~~improper isjurisdiction. The ~~currently~~Plaintiffs inhave ~~settlement~~not ~~negotiations~~filed ~~while~~another incomplaint ~~the~~since ~~initial motion stages of~~ the ~~litigation~~dismissal.

Our wholly owned subsidiary, SarahCare, is not involved in any other legal proceedings at this time, other than the legal proceedings listed above.

Except as set forth herein, no director, officer or affiliate is (i) a party adverse to us in any legal proceeding, or (ii) has an adverse interest to us in any legal proceedings, and management is not aware of any other legal proceedings pending or that have been threatened against us or our properties.

Table of Contents

Item 1A. Risk Factors.

As a smaller reporting company, we are not required to provide the information required by this item.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

During the quarter ended ~~December~~March 31, ~~2024~~2025, the Company did not have any unregistered sales of any equity securities.

Item 3. Defaults Upon Senior Securities.

During the quarter ended ~~December~~March 31, ~~2024~~2025, the Company was in default under the majority of its outstanding legacy convertible notes.

Item 4. Mine Safety Disclosure

Not applicable.

Item 5. Other Information.

None.

Table of Contents

Item 6. Exhibits.

See the Exhibit Index following the signature page of this Registration Statement, which Exhibit Index is incorporated herein by reference.

Exhibit	~~Description~~		Description
3.1	~~Certificate of Incorporation (New Jersey) (Incorporated by reference to the Company’s Form 10SB filed with the SEC on June 29, 2005)~~		Certificate of Incorporation (New Jersey) (Incorporated by reference to the Company’s Form 10SB filed with the SEC on June 29, 2005)
3.2	~~Bylaws (Incorporated by reference to the Company’s Form 10SB filed with the SEC on June 29, 2005)~~		Bylaws (Incorporated by reference to the Company’s Form 10SB filed with the SEC on June 29, 2005)
3.3	~~Certificate of Amendment of Certificate of Incorporation (Incorporated by reference to the Company’s Current Report on Form 8 K filed with the SEC on January 27, 2006)~~		Certificate of Amendment of Certificate of Incorporation (Incorporated by reference to the Company’s Current Report on Form 8 K filed with the SEC on January 27, 2006)
3.4	~~Certificate of Incorporation (Delaware)~~		Certificate of Incorporation (Delaware)
3.5	~~Certificate of Merger (redomiciling from New Jersey to Delaware)~~		Certificate of Merger (redomiciling from New Jersey to Delaware)
3.6	~~Certificate of Amendment to Certificate of Incorporation~~		Certificate of Amendment to Certificate of Incorporation
3.7	~~Certificate of Designation of Series A Convertible Preferred Stock~~		Certificate of Designation of Series A Convertible Preferred Stock
10.1+	~~Standard Office Lease by and between DeVille Developments, LLC, and Sarah Adult Day Services, Inc., dated June 2, 2017~~		Standard Office Lease by and between DeVille Developments, LLC, and Sarah Adult Day Services, Inc., dated June 2, 2017
10.2+	~~Lease by and between Stow Professional Center, LLC, and Sarah Day Care Centers, Inc., dated September 4, 2014~~		Lease by and between Stow Professional Center, LLC, and Sarah Day Care Centers, Inc., dated September 4, 2014
10.3+	~~Lease Agreement by and between S. Frank Prof. Bldg., LLC, and Sarah Day Care Centers, Inc., dated March 20, 2018~~		Lease Agreement by and between S. Frank Prof. Bldg., LLC, and Sarah Day Care Centers, Inc., dated March 20, 2018
10.4+	Stock Purchase Agreement by and among Innovative MedTech, Inc., Sarah Adult Day Services, Inc., Sarah Day Care Centers, Inc., The Sellers Named Herein, Dr. Merle Griff, as the Seller Representative, and Veteran Services LLC, dated as of March 25, 2021		Stock Purchase Agreement by and among Innovative MedTech, Inc., Sarah Adult Day Services, Inc., Sarah Day Care Centers, Inc., The Sellers Named Herein, Dr. Merle Griff, as the Seller Representative, and Veteran Services LLC, dated as of March 25, 2021
10.5	~~Share Exchange Agreement, by and between Innovative MedTech, Inc., VC Bin, LLC, Webb Media, LLC, Melides Capital, LLC, Ronald Schreiber, and Dovner Holdings, LLC, dated April 26, 2022~~		Share Exchange Agreement, by and between Innovative MedTech, Inc., VC Bin, LLC, Webb Media, LLC, Melides Capital, LLC, Ronald Schreiber, and Dovner Holdings, LLC, dated April 26, 2022
10.6	~~Executive Employment Agreement between Innovative MedTech, Inc. and Dr. Merle Griff, dated May 2, 2022~~		Executive Employment Agreement between Innovative MedTech, Inc. and Dr. Merle Griff, dated May 2, 2022
10.7	~~Consulting Agreement between Innovative MedTech, Inc. and Red Halo, LLC, dated May 2, 2022~~		Consulting Agreement between Innovative MedTech, Inc. and Red Halo, LLC, dated May 2, 2022
10.8	~~Exclusive License Agreement by and between Innovative MedTech, Inc. and Shearson Kershman Labs, dated May 17, 2024~~		Exclusive License Agreement by and between Innovative MedTech, Inc. and Shearson Kershman Labs, dated May 17, 2024
14.1	Code of Ethics (Incorporated by reference to the Company’s Form SB-2 filed with the SEC on May 12, 2006)
10.9			Asset Purchase Agreement, by and between Innovative MedTech, Inc., and Grand Concierge, LLC d/b/a/ Ticketbash, dated April 25, 2025 (incorporated by reference to Exhibit 10.1 to Current Report on Form 8-K filed on May 1, 2025)
31.1*	Certification of the Chief Executive Officer pursuant to Rule 13a-14(a) or 15d-14(a) under the Securities Exchange Act of 1934, as amended, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
14.1		Code of Ethics (Incorporated by reference to the Company’s Form SB-2 filed with the SEC on May 12, 2006)
31.2*	Certification of the Chief Financial Officer pursuant to Rule 13a-14(a) or 15d-14(a) under the Securities Exchange Act of 1934, as amended, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
31.1*		Certification of the Chief Executive Officer pursuant to Rule 13a-14(a) or 15d-14(a) under the Securities Exchange Act of 1934, as amended, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
32.1*	Certification of the Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
31.2*		Certification of the Chief Financial Officer pursuant to Rule 13a-14(a) or 15d-14(a) under the Securities Exchange Act of 1934, as amended, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
32.2*	Certification of the Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
32.1*		Certification of the Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
101.INS*	Inline XBRL Instance Document (the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document)
32.2*		Certification of the Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
101.SCH*	Inline XBRL Taxonomy Extension Schema Document
101.INS*		Inline XBRL Instance Document (the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document)
101.CAL*	Inline XBRL Taxonomy Extension Calculation Linkbase Document
101.SCH*		Inline XBRL Taxonomy Extension Schema Document
101.DEF*	Inline XBRL Taxonomy Extension Definition Linkbase Document
101.CAL*		Inline XBRL Taxonomy Extension Calculation Linkbase Document
101.LAB*	Inline XBRL Taxonomy Extension Labels Linkbase Document
101.DEF*		Inline XBRL Taxonomy Extension Definition Linkbase Document
101.PRE*	Inline XBRL Taxonomy Extension Presentation Linkbase Document
101.LAB*		Inline XBRL Taxonomy Extension Labels Linkbase Document
104*	Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)
101.PRE*		Inline XBRL Taxonomy Extension Presentation Linkbase Document
104*		Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)

~~______________~~________

Filed herewith

Certain schedules and exhibits have been omitted pursuant to Item 601(b)(2) and/or Item 601(a)(5) of Regulation S-K. A copy of any omitted schedule or exhibit will be furnished supplementally to the Commission upon request; provided, however, that the Company may request confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended, for any schedule or exhibit so furnished.

* Filed herewith

+ Certain schedules and exhibits have been omitted pursuant to Item 601(b)(2) and/or Item 601(a)(5) of Regulation S-K. A copy of any omitted schedule or exhibit will be furnished supplementally to the Commission upon request; provided, however, that the Company may request confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended, for any schedule or exhibit so furnished.

Table of Contents

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

Innovative MedTech, Inc. (Registrant) /s/ Michael Friedman Michael FriedmanChief Executive Officer Date: ~~February~~May 1820, 2025

Filing Compare · AnTix Holdings, Inc.